PF-08044562 (Combination COVID -19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 1A PHASE 1/2 RANDOMIZED STUDY TO EVALUATE TH E SAFETY, 
TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA COVID -19
VACCINE AND A RECOMBINANT INFLUENZ A VACCINE ADMINISTERED AS 
A SINGLE INJECTION IN HEALTHY ADULTS 50YEARS OF AGE OR OLD ER
Study Intervention Number : PF-08044562
Study Intervention Name: [CONTACT_228016] D-19Vaccine and RI V
USIND Number: Not Available
EudraCT /EU CTNumber: Not Applicable
ClinicalTrials.gov ID:  Not Available
Pediatric Investigational Plan Number: Not A pplicable
Protocol Number: C5681001
Phase: 1/2
Sponsor Legal Address: [COMPANY_007] I nc.
[ADDRESS_799325]
[LOCATION_001], NY [ZIP_CODE]
Brief Title: A Study  to Evaluate the Safety , Tolerability , and Immunogenicity  of a 
COVID- 19Vaccine andanInfluenza Vaccine Given as a Single Injection in Healthy 
Adults
This document and accompanying materials contain confidential information belonging to [COMPANY_007]. Except as 
otherwise agreed to in writing, by [CONTACT_185586] s, you agree to hold this 
information in confidence and not copy or disclose it to others (except where required by [CONTACT_87117] ) or 
use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, [COMPANY_007] must 
be promptly notified.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 2Document History
Document Version Date
Original protocol 18December 2023
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 3TABLE OF CONTENTS
LIST OF TABLES ................................ ................................ ................................ ..................... 8
1. PROTOCOL  SUMMARY .....................................................................................................9
1.1. Sy nopsis ....................................................................................................................9
1.2. Schema ....................................................................................................................18
1.3. Schedule of Activities .............................................................................................19
2. INTRODUCTION ...............................................................................................................22
2.1. Study  Rationale .......................................................................................................22
2.2. Background .............................................................................................................22
2.2.1. Clinical Overview .......................................................................................23
[IP_ADDRESS]. BNT162b2 ................................ ................................ ................. 23
[IP_ADDRESS]. RI V ............................................................................................24
2.3. Benefit/Risk Assessment
.........................................................................................25
2.3.1. Risk Assessment
.........................................................................................26
2.3.2. Benefit Assessment .....................................................................................29
2.3.3. Overall Benefit/Risk Conclusion ................................................................29
3. OBJECTI VES, ENDPO INTS, AND ESTIMANDS ...........................................................29
4. STUDY DESIGN .................................................................................................................31
4.1. Overall Design .........................................................................................................31
4.2. Scientific Rationale for Study  Design .....................................................................33
4.2.1. Choice of Contraception/Barrier Requirements .........................................33
4.3. Justification for Dose ..............................................................................................33
4.3.1. Monovalent BNT162b2 (Omi XBB.1.5) ....................................................33
4.3.2. RI V
.............................................................................................................33
4.3.3. BNT162b2 (Omi XBB.1.5)/RIV ................................................................33
4.4. End of Study  Definition ..........................................................................................33
5. STUDY POPUL ATION
................................ ................................ ................................ ......33
5.1. I nclusion Criteria .....................................................................................................34
5.2. Exclusion Criteria ....................................................................................................35
5.3. L ifesty le Considerations ..........................................................................................37
5.3.1. Contraception ..............................................................................................37
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 45.4. Scr een Failures ........................................................................................................37
5.5. Criteria for Temporarily  Delay ing 
Enrollment/Randomization/Administration of Study  Intervention ...........................37
6. STUDY INTERVENTIO N(S) AND CONCOMITANT THERAPY .................................38
6.1. Study  Intervention(s) Administered ........................................................................38
6.1.1. Administration ............................................................................................41
6.1.2. Medical Devices .........................................................................................41
6.2. Preparation, Handling, Storage, and Accountability ...............................................41
6.2.1. Preparation and Dispensing ........................................................................42
6.3. Assignment to Study I ntervention ...........................................................................43
6.4. Blinding
...................................................................................................................43
6.4.1. Blinding of Participants ..............................................................................43
6.4.2. Blinding of Site Personnel ..........................................................................43
6.4.3. Blinding of the Sponsor
..............................................................................43
6.4.4. Breaking the Blind ......................................................................................43
6.5. Study  Intervention Compliance ...............................................................................43
6.6. Dose Modification ...................................................................................................43
6.7. Continued Access to Study  Intervention After the End of the Study ......................44
6.8. Treatment of Overdose
............................................................................................44
6.9. Prior and Concomitant Therap y
..............................................................................44
6.9.1. Prohibited During the Study .......................................................................44
6.9.2. Permitted During the Study ........................................................................45
7. DI SCONTINUATION O F STUDY 
INTERVENTION AND PARTI CIPANT 
DISCO NTINUAT ION/WI THDRAWA L...........................................................................45
7.1. Discontinuation of Study  Intervention ....................................................................45
7.2. Participant Discontinuation/Withdrawal From the Study .......................................[ADDRESS_799326] to Follow -Up...................................................................................................47
8. STUDY ASSESSMENTS AND PROCEDURES ...............................................................47
8.1. Administrative Procedures ......................................................................................47
8.1.1. Telehealth Visits .........................................................................................48
8.2. Efficacy  and/or Immunogenicity
 Assessments .......................................................48
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 58.2.1. Testing for SARS- CoV -2 and Influenza Exposure ....................................49
8.2.2. Biological Samples .....................................................................................49
8.3. Safet y Assessments .................................................................................................49
8.3.1. Phy sical Examinations ................................................................................49
8.3.2. Vital Signs ..................................................................................................50
8.3.3. Clinical Safety  Laboratory  Assessments ....................................................50
8.3.4. Electronic Diary ..........................................................................................50
[IP_ADDRESS]. Grading Scales ...........................................................................51
[IP_ADDRESS]. L ocal Reactions .........................................................................51
[IP_ADDRESS]. Sy stemic Events ........................................................................52
[IP_ADDRESS]. Fever ..........................................................................................53
[IP_ADDRESS]. Antipy retic Medication .............................................................54
8.3.5. Phase 1 Stoppi[INVESTIGATOR_1869] ..............................................................................54
8.3.6. Pregnancy  Testing ......................................................................................55
8.4. Adverse Events, Serious Adverse Events, and Other Safet y Reporting .................55
8.4.1. Time Period and Frequency  for Collecting AE and SAE Information .......56
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety ...............................................57
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
...................57
8.4.2. Method of Detecting AEs and SAEs ..........................................................57
8.4.3. Follow -Up of AEs and SAEs ......................................................................57
8.4.4. Regulatory
 Reporting Requirements for SAEs ...........................................58
8.4.5. Environmental Exposure, Exposure During Pregnancy  or 
Breastfeeding, and Occupational Exposure .....................................................58
[IP_ADDRESS]. Exposure During Pregnancy ................................ ...................... 58
[IP_ADDRESS]. Exposure During Breastfeeding ................................................60
[IP_ADDRESS]. Occupational Exposure .............................................................60
8.4.6. Cardiovascular and Death Events ................................ ............................... 60
8.4.7. Disease -Related Events and/or Disease -Related Outcomes Not 
Qualifying as AEs or SAEs ..............................................................................[ADDRESS_799327] .............................................................61
[IP_ADDRESS]. Lack of Efficacy ........................................................................61
8.4.9. Medical Device Deficiencies ................................ ................................ ......61
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page [IP_ADDRESS]. Time Period for Detecting Medical Device Deficiencies .........62
[IP_ADDRESS]. Follow -
Up of Medical Device Deficiencies..............................62
[IP_ADDRESS]. Regulatory  Reporting Requirements for Device 
Deficiencies .......................................................................................62
8.4.10. Vaccination Errors
....................................................................................63
8.5. Pharmacokinetics ....................................................................................................64
8.6. G enetics ...................................................................................................................64
8.7. Biomarkers ..............................................................................................................64
8.8. I mmunogenicit y Assessments .................................................................................64
8.9. Health Economics ...................................................................................................64
8.10. Study  Procedures ...................................................................................................64
8.10.1. Visit 1 
–Vaccination (Day 1) ...................................................................64
8.10.2. Visit 2 
– 4-Week Follow -Up Visit (After Vaccination) – 28 to 35 
Days After Visit 1 ............................................................................................67
8.10.3. Visit 3 
– 6-Month Follow -Up Visit (After Vaccination) – 175 to 
189 Day s After Visit 1 .....................................................................................67
8.10.4. Unscheduled Visit for a Grade 3 or Suspected Grade 4 Reaction ............68
8.10.5. Additional Procedures for Monitoring of Potential My ocarditis or 
Pericarditis .......................................................................................................69
8.10.6. Additional Procedures for Monitoring of Potential Menstrual Cy cle 
Disturbances .....................................................................................................69
9. STATI STICAL CONSI DERATIONS
................................................................................70
9.1. Statistical Hy potheses .............................................................................................70
9.1.1. Estimands ....................................................................................................70
9.1.2. Multiplicity  Adjustment ..............................................................................70
9.2. Analy sis Sets ...........................................................................................................70
9.3. Statistical Analy ses.................................................................................................71
9.3.1. General Considerations ................................ ................................ ............... 71
[IP_ADDRESS]. Analy sis for Binary  Data ...........................................................71
[IP_ADDRESS]. Analy sis for Continuous Data ...................................................72
9.3.2. Primary  Endpoint(s)/Estimand(s) Anal ysis................................ ................ 73
9.3.3. Secondary  Endpoint(s)/Estimand(s) Anal ysis............................................73
9.3.4. Tertiary /Exploratory  Endpoint(s) Anal ysis................................ ................ 74
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 79.4. I nterim Anal yses.....................................................................................................75
9.4.1. Analy sis Timing ..........................................................................................75
9.5. Sample Size Determination .....................................................................................75
10. SUPPORTING DOCUM ENTATION AND OPERATI ONAL 
CONSI DERATIONS
..........................................................................................................76
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversight Consi derations ...............76
10.1.1. Regulatory and Ethical Considerations ....................................................76
[IP_ADDRESS]. Reporting of Safety  Issues and Serious Breaches of the 
Protocol or I CH GCP .........................................................................76
10.1.2. Financial Disclosure .................................................................................77
10.1.3. I nformed Consent Process ........................................................................77
[IP_ADDRESS]. Electronic Consent
..................................................................78
10.1.4. Data Protection .........................................................................................78
10.1.5. Committees Structure ...............................................................................79
[IP_ADDRESS]. Data Monitoring Committee ...................................................79
10.1.6. Dissemination of Clinical Study  Data ......................................................79
10.1.7. Data Qualit y Assurance ............................................................................80
10.1.8. Source Documents ....................................................................................81
10.1.9. Use of Medical Records ............................................................................82
10.1.10. Study  and Site Start and Closure ............................................................82
10.1.11. Publication Policy ...................................................................................83
10.1.12. Sponsor’s Medically  Qualified Individual ..............................................84
10.2. Appendix 2: Clinical Laboratory  Tests .................................................................85
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting .....................................................................86
10.3.1. Definition of AE .......................................................................................86
10.3.2. Definition of an SAE ................................................................................87
10.3.3. Recording/Reporting and Follow
-Up of AEs and/or SAEs During 
the Active Collection Period ............................................................................89
10.3.4. Reporting of SAEs
....................................................................................92
10.4. Appendix 4: Contraceptive and Barrier Guidance ................................ ................ 94
10.4.1. Male Participant Reproductive Inclusion Criteria ....................................94
10.4.2. Female Participant Reproductive Inclus ion Criteria ................................ .94
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 810.4.3. Woman of Childbearing Potential ............................................................95
10.4.4. Contraception Methods .............................................................................96
10.5. Appendix 5: L iver Safety : Suggested Actions and Follow -Up Assessments .......98
10.6. Appendix 6: Kidney  Safety  Monitoring Guide lines ...........................................100
10.6.1. Laboratory  Assessment of Change in Kidney  Function and 
Detection of Kidney  Injury ............................................................................100
10.6.2. Age -Specific Kidney  Function Calculation Recommendations .............100
[IP_ADDRESS]. Adults (18 Years and Above) —2021 CKD - EPI 
[INVESTIGATOR_185560] .........................................................................................100
10.6.3. Kidney
 Function Calculation Tools........................................................101
10.6.4. Adverse Event Grading for Kidney  Safet y Laboratory  
Abnormalities .................................................................................................101
10.7. Appendix 7: AEs, ADEs, SAEs, SADEs, [LOCATION_003]DEs, and Device 
Deficiencies: Definitions and Procedures for Recording, Evaluating, 
Follow -Up, and Reporting in M edical Device Studies ...........................................102
10.7.1. Definition of AE and ADE .....................................................................102
10.7.2. Definition of SAE, SADE, and [LOCATION_003]DE ................................................102
10.7.3. Definition of Device Deficiency .............................................................103
10.7.4. Recording/Reporting and Follow
-Up of Medical Device 
Deficiencies ....................................................................................................103
10.8. Appendix 8: Abbreviations
.................................................................................[ADDRESS_799328] OF TABLES
Table 1. Schedule of Activities ................................ ................................ ............... 19
Table 2. Phase 1/[ADDRESS_799329] 1 AE, b y Assumed True Event 
Rate ................................ ................................ ................................ ........... 75
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 91.PROTOCOL SUMMARY 
1.1.Synopsis 
Protocol Title: A Phase 1/2 Randomized Study  to Evaluate the Safet y, Tolerability, a nd 
Immunogenicit y of a Modified RNA COVID -19 Vaccine and a Recombinant I nfluenza 
Vaccine Administered as aSingle Injection i n Healthy  Adults 50 Years of Age or Older
Brief Title: A Study  to Evaluate the Safety , Tolerability , and Immunogenicity  of a 
COVID -
19 Vaccine and an Influenza Vaccine Given as a Single Injection in Healthy  Adults
Regulatory Agency Identification Number(s):
US IND Number: Not Available
EudraCT /EU CTNum ber: Not Applicable
ClinicalTrials.gov ID:  Not Available
Pediatric Investigational Plan Number : Not Applicable
Protocol Num ber: C5681001
Phase: 1/2
Rationale :
BNT162b2 (Comirnat y®) is a messenger ribonucleic acid ( mRNA )
-based vaccine that ,as of 
January  2023, has been granted full marketing authorization, conditional marketing 
authorization, emergency use authorization ( EUA ), or temporary  authorization in a total of 
more than 184 countries for the prevention of coronavirus disease 2019 ( COV ID-19) caused 
by [CONTACT_11550][INVESTIGATOR_19960] 2 ( SARS -CoV - 2). The original version 
ofBNT162b2 encodes the ancestral Wuhan -Hu-1 strain spi[INVESTIGATOR_603691]. I n the 
[LOCATION_002] ( US), it has been full y licensed for use in individuals 12 y ears of age and above 
as of 08 July  2022. All versions of the vaccine encode the SARS -CoV -2 spi[INVESTIGATOR_144870](s) in 
nucleoside -modified messenger ribonucleic acid ( modRNA )encapsulated in ribonucleic acid
lipid nanoparticles ( RNA -LNPs ), which has demonstrated potent immunogenicity , high 
vaccine efficacy  (VE), and a favorable safet y profile in Phase 1, 2, and 3 human trials, as 
well as in real -world usage. As SARS -CoV -2 continues to circulate, at very  high levels, 
[COMPANY_007]/BioNTech are inv estigating RNA -based COVID -[ADDRESS_799330] 
COVID -
19 caused b y em ergent and potentiall y more antigenically  diverse variants. 
BNT162b2 ( Omicron [Omi] XBB.1.5), a monovalent vaccine containing mRNA encoding 
the spi[INVESTIGATOR_603692]. 1.5 variant, will be used in this study  as this is the variant 
recommended b y the Food and Drug Administration ( FDA )beginning in fall 2023.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 10Flublok Quadrivalent (referred to as RIV [recombinant influenza virus] ) is a recombinant 
influenza vaccine, manufac tured in a baculovirus expression vector and insect cell culture 
system, consisting of 
4recombinant influenza hemagglutinin (HA) antigens derived from 
influenza virus ty pe A, subty pes H1 and H3, and 2type B virus strains (lineages B/Victoria 
and B/Yamaga ta). HA genes from each of the 4influenza viruses are inserted into a plasmid 
baculovirus expression vector s ystem (BEVS) and expressed in Spodoptera frugiperda insect 
cells. RI Vis indicated for active immunization against influenza disease caused by  [CONTACT_14302] 
A subty pe viruses and t ype B viruses contained in the vaccine, for use in adults [ADDRESS_799331] both pathogens.
This Phase 1/2 study  will evaluate the safet y, reactogenicity, and immunogenicity of 
BNT162b2 (Omi XBB.1.5) andRIV administered asa mixture ina single injection . 
Objectives , Endpoints ,and Estimands :
Objectives Endpoints Estimands
Prim ary: Prim ary: Prim ary: 
Safety
To describe the safety and 
tolerability of the study 
interventionsLocal reactions (pain at the 
injection site, redness, and 
swelling) 
Systemic events (fever, 
fatigue, headache, chills, 
vomiting, diarrhea, new or 
worsened muscle pain, and 
new or worsened joint pain)
Adverse events ( AEs)
Serious adverse events ( SAEs )The percentage of participants 
receiving at least 1 dose of study 
intervention reporting:
Local reactions for up to 
7days following vaccination
Systemic events for up to 
7days following vaccination
AEs from vaccination 
through 4 weeks after 
vaccination
SAEs from vaccination 
through 6 months after 
vaccination
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 11Objectives Endpoints Estimands
Immunogenicity
To describe the immune responses 
elicited by [CONTACT_214326]162b2 
(Omi XBB.1.5) /RIV, BNT162b2 
(Omi XBB.1.5) + RIV 
coadministered, and BNT162b2 
(Omi XBB.1.5) and RIV 
administered alone (4 w eeks after 
vaccination)SARS -CoV- 2 
Omicron (XBB.1.5) –neutralizing 
titersIn participants complying with the 
key protocol criteria 
(evaluable participants):
Geom etric mean titers 
(GMTs )before vaccination 
and at 4  weeks after 
vaccination 
Geom etric mean fold rise 
(GMFR )from before 
vaccination to 4 w eeks after 
vaccination 
Percentage of participants 
with seroresponseaat 4 weeks 
after vaccination
Hem agglutinin inhibition assay 
(HAI) titers against the seasonal 
strains recommended by [CONTACT_103210] (WHO) for the 
northern hemisphere 2023 -2024 
influenza seasonIn participants complying with the 
key protocol criteria 
(evaluable participants):
GMTs before vaccination and 
at 4 w eeks after vaccination
GMFRs from before 
vaccination to 4 weeks after 
vaccination 
The percentages o f 
participants achieving HAI 
seroconversionbat 4 w eeks 
after vaccination 
The percentages of 
participants with HAI titers 
≥1:40 before vaccination and 
at 4 w eeks after vaccination
a.Seroresponse is defined as achieving a ≥4-fold rise from baseline (before the stud y vaccination). If the 
baseline measurement is below the lower limit of quantitation ( LLOQ ), the postvaccination measure of 
≥4 × LLOQ is considered seroresponse.
b.Seroconversion is defined as an HAI titer 1:10 prior to vaccination and ≥ 1:[ADDRESS_799332], or an HAI titer of ≥1:[ADDRESS_799333].
Overall Design:
This is a Phase 1/2 single -blind (site -and sponsor -unblinded) study  to evaluate the safet y, 
tolerability
, and immunogenicity  of licensed BNT162b2 (Omi XBB.1.5) and RI V 
administered together asa single injection (referred to as BNT162b2 [Omi XBB.1.5]/ RIV)in 
healthy  adults 5 0 years of age or older. 
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 12The safet y, tolerability , and immunogenicit y of BNT162b2 (OmiXBB1.5) /RIV administered 
asa single injection will be compared to BNT162b2 (Omi XBB.1.5) +RIV administered 
simultaneously  as 2 separate injections (coadministered), and to BNT162b2 (Omi XBB.1.5) 
or RIV when administered alone. 
Across Phases1 and 2, approximately  640 participants in total will be randomized with an 
equal randomization ratio (1:1:1:1 )to each of the following vaccine groups and stratified b y 
age group (50 through 64 y ears of age and ≥65 years of age) :  
Group 
1:BNT162b2 (Omi XBB.1.5) /RIV (as a single injection) administered in the left 
deltoid and placebo administered in the right deltoid
Group 2: BNT162b2 (Omi XBB.1.5) ad ministered in the left deltoid and RIV 
administered in the right deltoid
Group 3: BNT162b2 (Omi XBB.1.5) administered in the left deltoid and placebo 
administered in the right deltoid
Group 4: RIV administered in the left deltoid and placebo administered i n the right 
deltoid
During Phase 1, a total of ~20 participants will be enrolled in each vaccine group. Enrollment 
of participants in each vaccine group will be controlled such that ~10participants 50 through 
64 years of age (sentinel participants, considered Phase 1a ) can be vaccinated in each of the 
groups on the first day . This will be monitored by  [CONTACT_456] ,
who will inform sites to pause 
enrollment once the target has been reached. Vaccination of the remaining ~40 participants 
(~10 per vaccine group) will commence no sooner than 24 hours after this safet y pause. The 
participants vaccinated after the safety  pause will be ≥65 years of age (considered Phase 1b). 
Once ~20participants per vaccine group have been vaccinated in Phase [ADDRESS_799334] ive 
response technology  (IRT)system will block any  further randomization, pending a review of 
at least 72hours of safety  data for all participants by  [CONTACT_603715] ( IRC). 
The outcome of the safety data review will be documented in a memo ,which will be 
circulated to all sites prior to starting enrollment in Phase 2. In Phase 2, approximately  
140participants 50 years of age or older will be enrolled in each of the 4vaccine groups. 
Participants will be stratified by  [CONTACT_551] , 50 through 64 y ears of age and ≥65 years of age .
Prespecified local reaction and sy stemic event data will be collected in an electronic diary  
(e-diary )during the 7 day s, or longer for ongoing sy mptoms, after stud y intervention 
(ie, from Day  1, the day  of vaccinati on, until sy mptom resolution), as well as any  
medication staken during this period to treat an y pain symptoms or fever . 
Blood samples of approximately  20 mL will be collected from all participants for 
immunogenicity assessments prior to vaccination and at 4 weeks and 6 months after 
vaccination.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 13Following vaccination, AEs will be collected from informed consent signing through Visit 2
(approximately  4 weeks after vaccination), and SAEs will be collected from informed 
consent signing through Visit 3 (approxi mately  6 months after vaccination). In addition, AEs 
occurring up to 48 hours after blood draws will also be collected.
Number of Participants:
Phase 1: Approximately  
80 participants will be enrolled. 
Phase 2: Approximately  560 participants will be enrolled.
Study Population :
Inclusion Criteria 
Participants must meet the following inclusion criteria to be eligible for enrollment into the 
study :
Age and Sex:
1.Male or female participants aged 50 y ears or older at Visit 1 (Day  1). 
Refer to the protocol 
for reproductive criteria for male and female participants .
Disease Characteristics:
Not applicable. 
Other Inclusion Criteria:
2.Participants who are willing and able to compl y with all scheduled visits, the 
investigational plan, laboratory  tests, lifest yle considerations, and other study  procedures.
3.Health y participants who are determined b y medical history, ph ysical examination 
(if required), and clinical judgment of the investigator to be eligible for inclusion in the 
study .
Note: Health y participants with preexisting stable disease, defined as disease not 
requiring significant change in therap y or hospi[INVESTIGATOR_76807] 6 weeks before enrollment, can be included. 
4. Capable of giving signed informed consent as described in the protocol, which includes 
compliance with the requirements and restrictions listed in the informed consent 
document ( ICD) and in this protocol.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 14Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Any medical or ps ychiatric condition including recent (within the past year) or active 
suicidal ideation/behavior or laboratory  abnormality  that may  increase the risk of study  
participation or, in the investigator’s judgment, make the par ticipant inappropriate for the 
study .
2.Known infection with human immunodeficiency  virus (HIV), hepatitis C virus (HCV), or 
hepatitis B virus (HBV).
3.History  of severe adverse reaction associated with any  vaccine and/or severe allergic 
reaction (eg, anaph ylaxis) to any  component of the study  interventions.
4.Participants with a history of autoimmune disease or an active autoimmune disease 
requiring therapeutic intervention, including but not limited to sy stemic or cutaneous 
lupus ery thematosus, autoimmune arthr itis/rheumatoid arthritis, multiple sclerosis, 
Sjögren’s s yndrome, idiopathic thrombocy topenia purpura, glomerulonephritis, 
autoimmune thy roiditis, temporal arteritis, psoriasis, and/or insulin -dependent diabetes 
mellitus.
5.Immunocompromised individuals with known or suspected immunodeficiency, 
determined b y history  and/or laboratory /physical examination.
Note: I ndividuals who have had a splenectom y or have functional asplenia will be 
considered ineligible. 
6.Current heart disease, uncontrolled hy pertensio n, or a prior history  of m yocarditis or 
pericarditis.
Note: 
Hypertension that has been controlled a minimum of 12 weeks, stable coronary  
artery  disease, and stable mild valvular disease are not exclusionary .
7. Bleeding diathesis or condition associated with prolonged bleeding that would, in the 
opi[INVESTIGATOR_871], contraindicate intramuscular injection.
8.
Women who are pregnant, plan to become pregnant during the study, or are 
breastfeeding.
9.Prior history  of ischemic stroke or transient ischemic attack.
10.Prior history  of Guillain- Barré syndrome (GBS) .
11.Participants with a calculated body  mass index ( BMI )of ≥35.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 15Prior/Concomitant Therapy:
12.Receipt of chronic medications with known sy stemic immunosuppressant effects 
(including cy totoxic agents or sy stemic corticosteroids), or radiotherapy , within 60 day s 
before enrollment through conclusion of the study.
Note: Sy stemic corticosteroids are defined as those administered for ≥ 14 day s at a 
dose of ≥20 mg/day  of prednisone or equivalent (eg, for cancer or an autoimmune 
disease) or planned receipt throughout the stud y. Inhaled/nebulized, intra -articular, 
intrabursal, or topi[INVESTIGATOR_2855] (skin or ey es) corticosteroids are permitted.
13.Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies used for 
the trea tment or prevention of COVID -19 or those that are considered 
immunosuppressive, from 90 days before study  intervention administration, or planned 
receipt throughout the study .
14.Vaccination with any  investigational or licensed influenza vaccine within 6mont hs 
(180 days) before stud y intervention administration, or ongoing receipt of chronic 
antiviral therap y with activity  against influenza.
15.Vaccination with any  investigational or licensed COVID -19 vaccine within 6months 
(180 days) before stud y intervention administration.
Prior/Concurrent Clinical Study Experience:
16.Participation in other studies involving administration of a ninvestigational product
within 28 day s prior to, and/or during, participation in this study .
Note: I n addition to administration of i nvestigational products, study  interventions 
may include additional procedures, such as collection of biological samples. 
Therefore, participants may  not be in another study  whereby  [CONTACT_43056], such as 
respi[INVESTIGATOR_603693], may  interfere with complia nce with this study ’s protocol.
Diagnostic Assessments:
Not applicable.
Other Exclusion Criteria:
17.Investigator site staff directly  involved in the conduct of the study  and their family  
members, site staff otherwise supervised b y the investigator, and sponsor and sponsor 
delegate employ ees directly  involved in the conduct of the study  and their family  
members.
18.Deprived of freedom b y an administrative or court order, or in an emergency  setting, or 
hospi[INVESTIGATOR_29476].
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 1619. Current alcohol abuse or drug addiction that in the opi[INVESTIGATOR_2511] i nvestigator might 
interfere with the study  conduct or completion.
Study Arms and Duration :
Study Intervention(s)
Intervention 
Nam eBNT162b2 (Omi 
XBB.1.5) /RIVBNT162b2 
(Omi XBB.1.5)RIV Normal saline 
placebo
Type mRNA and
recombinant 
protein vaccine mRNA vaccine Recombinant 
protein vaccinePlacebo
Use Experimental Com parator Com parator Placebo for 
blinding
Investigational 
Medicinal Product 
(IMP )or 
Noni nvestigational 
Medicinal P roduct 
(NIMP )/Auxiliary 
Medicinal Product 
(AxMP )IMP IMP IMP IMP
Dose Form ulation Suspension for 
injection and 
recombinant Suspension for 
injectionSolution for 
injectionNormal saline 
(0.9% sodium 
chloride solution 
for injection)
Unit Dose 
Strength(s)As detailed in the 
investigational 
product manual 
(IPM)As detailed in the 
IPMAs detailed in the 
IPMNot applicable 
(N/A)
Targeted 
Influenza StrainsAs recommended 
by [CONTACT_603716] -based 
vaccines 
(2023 -2024 
northern 
hemisphere 
influenza season )aN/A As recommended 
by [CONTACT_603716] -based 
vaccines 
(2023 -2024 
northern 
hemisphere 
influenza season )aN/A
Dosage Level(s) BNT162b2 
(Omi XBB.1.5) 
30µg
RIV 180 µg30 µg mRNA 180 µg 
Recom binant 
protein0.5mL
Route of 
AdministrationIntramuscular 
injectionIntramuscular 
injectionIntramuscular 
injectionIntramuscular 
injection
Sourcing Provided centrally 
by [CONTACT_603717]
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 17Study Intervention(s)
Packaging and 
LabelingStudy intervention 
will be generated 
by [CONTACT_603718]- level 
combinations 
detailed below :
BNT162b2 
(Omi 
XBB.1.5)
RIV 
Each vial will be 
labeled per country 
requirementStudy intervention 
will be provided in 
a glass vial as 
open -label supply. 
Each vial will be 
labeled per country 
requirementStudy intervention 
will be provided as 
either a PFS or a 
glass/plastic vial as 
open -label supplyStudy intervention 
will be provided in 
a plastic vial as 
open -label supply
Single Reference 
Safety Docum ent 
(SRSD )Com bined 
investigator’s 
brochures ( IBs)IB Flublok IB N/A
a.For the 2023 -2024 influenza season ,Flublok Quadrivalent is formulated to contain 180 µ g HA per 
0.5-mL dose, w ith 45 µ g HA of each of the following 4 influenza virus strains: A/West Virginia/30/2022 
(A/Wisconsin/67/2022 pdm09 -like virus) (H1N1), A/Darwin/6/2021 (H3N2), B/Austria/1359417/2021 ,
and B/Phuket/3073/2013.
Statistical Methods :
The sample size is not based on an y formal hypothesis test. All statistical analyses will be 
descriptive. Data from Phase 1 and Phase 2 participants will be combined forthe safet y and 
immunogenicit y anal yses.
Thesafet y primary  objective will be evaluated b y descriptive summary  statistics for local 
reactions, s ystemic events, AEs
, and SAEs for each vaccine group. The immunogenicit y 
primary  objective will be evaluated de scriptivel y by [CONTACT_603719] -CoV - 2 
Omicron (XBB.1.5) –neutralizing titers and strain- specific HAI titers (for the seasonal strains 
recommended b y WHO) , percentage sof participants with seroresponse to SARS -CoV -
2 
Omicron (XBB.1.5) , percentages of participants with HAI seroconversion and HAI 
titers ≥1:40, and the associated 2 -sided 95% CIs, for each vaccine group . 
Ethical Considerations :
Potential risks to individual participants may  include the following, mitigations for which are 
detailed in the protocol:
The safet y profile of administering BNT162b2 and RI V concomitantly  as a single 
vaccine is not yet full y characterized, so the full extent of risks is unknown.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 18Local reactions, such as injection site redness, injection site swellin g, and injection site 
pain, and s ystemic events, such as fever, fatigue, headache, chills, vomiting, diarrhea ,
muscle pain, and joint pain.
Cases of anaph ylaxis, my ocarditis, and pericarditis have been reported after authorization 
in recipi[INVESTIGATOR_250950]162b2. 
Venipuncture will be performed during the stud y. There is the risk of bleeding, bruising, 
hematoma formation, and infection at the venipuncture site.
Benefits to individual participants may  be:
Receipt of at least 1licensed vaccine against COVID -[ADDRESS_799335] to the 
participant, and provision of the immunogenicit y results.
Contributing to research to help others.
1.2.Schema
Phase 1
N = 80
Group 1
BNT162b2 /RIV ( 1.0mL)
+
placebo ( 0.5mL)Group 2
RIV (0.5 m L)
+
BNT162b2 (0.3 mL)Group 3
BNT162b2 (0.3 mL)
+
placebo ( 0.5mL)Group 4
RIV (0.5 m L)
+
placebo ( 0.5mL)
Phase 1a (Participants 50 through 64 years of age)
Sentinel
n = 10Sentinel
n = 10Sentinel
n = 10Sentinel
n = 10
Sponsor Safety Data Revie wa
Phase 1b (Participants ≥65 years of age)
n = 10 n = 10 n = 10 n = 10
IRCb
Phase 2 N = 560
Participants ≥50 years of age
n = 140 n = 140 n = 140 n = [ADDRESS_799336] been vaccinated.  
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 191.3. S chedule of Activ ities
The SoA table provides an overview of the protocol visits and procedures. Refer to the STUDY  ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may  schedule visits (unplanned visits) in addition to those listed in the SoA table, in order to conduct evaluations or 
assessments required to protect the well -being of the participant.
Table 1. Schedule of Activities
Visit Identifier 1 2 3 Notes
Visit Window Day 1 28 to 35 Days 
After Visit 1175 to 189 
Days After 
Visit 1Day 1 = Day of Vaccination
Visit Description Vaccination 4-Week 
Follow -Up 
Visit6-Month 
Follow -Up 
Visit
Visit Type/Location Site Site Site
Obtain informed consent X Informed consent should be obtained prior 
to undergoing any study -specific 
procedures.
See Section 10.1.[ADDRESS_799337] on WOCBP X See Section 8.3.6 for additional information. 
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 20Table 1. Schedule of Activities
Visit Identifier 1 2 3 Notes
Visit Window Day 1 28 to 35 Days 
After Visit 1175 to 189 
Days After 
Visit 1Day 1 = Day of Vaccination
Visit Description Vaccination 4-Week 
Follow -Up 
Visit6-Month 
Follow -Up 
Visit
Visit Type/Location Site Site Site
Confirm use of contraceptives (if appropriate) X X See Section 5.3.[ADDRESS_799338] blood sample for immunogenicity assessment ~20 mL ~20 mL ~20 mL See Section 8.2for additional information.
For laboratory collection volumes, see the 
laboratory manual.
Administer study intervention X
Postvaccination observation (at least 30 minutes) and 
assessment of immediate eventsX
Explain participant communication methods (including 
for reactogenicity e -diary completion), assist the 
participant with downloading the application, or issue 
provisioned device, if requiredX See Section 8.3.4 for additional information.
Provide/ensure the participant has a thermometer and 
measuring deviceX
Revie w reactogenicity e -diary data (daily review is 
optimal during the active reactogenicity e -diary period 
[Day s 1 through 7])
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 21Table 1. Schedule of Activities
Visit Identifier 1 2 3 Notes
Visit Window Day 1 28 to 35 Days 
After Visit 1175 to 189 
Days After 
Visit 1Day 1 = Day of Vaccination
Visit Description Vaccination 4-Week 
Follow -Up 
Visit6-Month 
Follow -Up 
Visit
Visit Type/Location Site Site Site
Site reviews e -diary data with participant follow -up 
until ongoing symptom/medication resolution, if 
applicableX X Revie w the participant’s e -diary data and record 
assessment in the CRF. Assess compliance, and 
any medically attended events (including 
hospi[INVESTIGATOR_602]). For symptoms still ongoing, 
continue to follow up until resolution, and 
document and record stop date s in the CRF.
Collect reactogenicity e -diary medication use X
Collect AEs and SAEs as appropriate X X X SeeSection 8.4for additional information.
AEs are collected from the completion of 
informed consent through Visit 2. SAEs are 
collected from the completion of informed 
consent through the end of study 
participation. Additionally, any AEs 
occurring up to [ADDRESS_799339] the participant with deleting 
the applicationX
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 222.INTRODUCTION
2.1.Study Rationale 
This Phase 1/2 study  will evaluate the safet y, tolerability , and immunogenicity  of licensed 
BNT162b2 (Omi XBB.1.5) and RIV
when administered together ina single injection to
healthy  adults [ADDRESS_799340] been used 
as a critical mitigation strategy  for the COVID -19 pandemic.
BNT162b2 (Comirnat y®) is an mRNA -based vaccine that, as of January  2023, has been 
granted full marketing authorization, conditional marketing authorization, EUA, or 
temporary  authorization i n a total of more than 184 countries for the prevention of 
COVID -
19 caused b y SARS -CoV -2.5The original version of BNT162b2 encodes the 
ancestral Wuhan- Hu-1 strain spi[INVESTIGATOR_603694]. In the US, it has been fully  licensed for use 
in individuals 12 y ears o f age and above as of 08 July  2022.6
With high background rates of population seropositivity , bivalent (original/Omi BA.4/BA.5) 
mRNA vaccines continued to provide effective protection against Omicron -related 
COVID -19,7,8,9,10,11,12including during periods of earl y XBB sublineage dominance.8  
Additional bivalent (original/Omi BA.4/BA.5) mRNA doses have been reported to have 
higher VE against Omicron than the original vaccine,13supporting the h ypothesis that better 
strain- matched vaccines improve protection against COVI D-19. However ,as of May  2023, 
the descendent sublineages of Omicron XBB (eg, XBB.1.5, XBB.1.16, XBB.1.9) have 
shown improved transmissibility  and reduced susceptibility to neutralization by  [CONTACT_603720] 
(original/Omi BA.4/BA.5) compared to earlier Omicron strains (eg, BA.1, BA.4, BA.5).[ADDRESS_799341] suggested potential waning VE of bivalent BA.4/BA.[ADDRESS_799342] severe illness, as well as less severe endpoints (ie, urgent/emergency  
care), roughl y [ADDRESS_799343] improved viral fitness, immune escape, and transmission is impacting 
VE over time.16On12 September 2023, t he Advisory  Committee on Immunization Practices 
(ACI P) recommended 
vaccination for all persons aged ≥ 6 months with the updated 
2023-2024 COVID - 19 vaccine including monovalent BNT162b2 (Omi XBB .1.5).17
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 23Influenza is a major cause of morbidity  and mortality  worldwide, occurring in annual 
seasonal epi[INVESTIGATOR_603695] y in global pandemics.18Symptomatic influenza infection 
causes a febrile illness with respi[INVESTIGATOR_432829] s ystemic sy mptoms,19although it ma y often be 
asymptomatic.20The risk of complic ations and hospi[INVESTIGATOR_603696] ≥ 65 years of age, y oung children, and people with certain underl ying medical 
conditions. I n the US, since 2010 an average of 445,[ADDRESS_799344] 
300,000 to over 600,000.22
Influenza viruses are part of the Orthom yxoviridae family  and are divided into 4 genera 
([ADDRESS_799345] humans [A, B, and C]) .21,23Influenza A viruses are further 
classified into subty pes based upon the membrane gl ycoproteins, HA and NA.23The RNA 
genome is segmented, which allows forgenetic reassortment among influenza A viruses .23
This genetic instability  can result in the phenomenon known as antigenic shift, involving a 
major change in one(HA) or both ( HA +NA) of the surface antigens, which, if efficientl y 
transmissible, can result in a pandemic. More common are multiple point mut ations in the 
genome, leading to more minor changes in the HA and NA, known as antigenic drift.21This 
genetic instability ,which can occur in influenza A, B ,andC,is what necessitates vaccines 
that are tailored annuall y.[ADDRESS_799346] available influenza vaccines require the culturing of influenza virus in chicken egg 
cells. The growth process not only introduces opportunity  for mutations that are antigenicall y 
mismatched to the circulating strain, but the process also requires man y months.24Flublok is 
a unique influenza vaccine that harnesses recombinant technology  to produce purified HA 
within 6 to 8 weeks.24,25  
There is a recommendation in the US for routine annual influenza vaccination for all persons 
aged ≥[ADDRESS_799347] contraindications.26
2.2.1. Clinical Overview
[IP_ADDRESS]. BNT162b2
Study  C4591001 ([STUDY_ID_REMOVED]) was a Phase 1/2/3 trial in ~47,[ADDRESS_799348] udy population: eligible 
participants ≥[ADDRESS_799349] IgG -binding response to S1 and a SARS -CoV -2–neutralizing r esponse. 
Immunogenicit y substantially  increased following the second dose of vaccine. BNT162b2 
induces a strong antigen -specific Th1
-skewed CD4+ response and a strong antigen-specific 
CD8+ response.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 24In a mid–November 2020 anal ysis of 36, 523participants ra ndomized 1:[ADDRESS_799350] 
7 day s after the second dose of vaccine was 95.0%, with 8 COVID -19 cases in the active 
vaccine group and 162 COVID -
19 cases in the placebo group.27
In a subsequent anal ysis of 927 confirmed s ymptomatic cases of COVID -19, an efficacy  rate 
of 91.3% was observed for BNT162b2 in preventing such cases occurring between [ADDRESS_799351] an efficacy of: 
100% in preventing severe disease as defined b y the CDC.
95.3% in preventing severe disease as defined b y the FDA.
100% in preventing COVID-[ADDRESS_799352] 16 y ears of age randomized 
1:1to vaccine or placebo with a median of 2 months of follow -up after the second dose 
demonstrated a favorable safet y profile. Available safet y data from all participants enrolled 
through the 14 November 2020 data cutoff (N = 43,252), which includes late enrollment of 
additional adolescent and adult participants, were consistent with the safet y profile for the 
approximately  38,[ADDRESS_799353] COVID -19. 
WHO issued its statement on the antigen composition of COVID- 19 vaccines on 
18May 2023 recommending use of a monovalent XBB.1 descendent lineage, such as 
XBB.1.5, as the vaccine antigen .7The EMA released similar guidance on 06 June 2023 
recommending that a monovalent vaccine targeting the XBB.1 descendent lineages be 
administered beginning in autumn 2023.29On 11 September 2023, the FDA approved 
authorization of a monovalent vaccine targeting the XBB.1.5 Omicron subvariant.30,31
[IP_ADDRESS]. RIV
RIVwas studied in a Phase 3 multicenter, randomized, double -blind controlled trial inadults 
65 years of age and older during the 2006-2007 influenza season where participants were 
randomized to 
RIV or a licensed trivalent influenza vaccine. The frequency and severit y of 
injection site reaction and sy stemic events after immunization were similar in both groups.
RIV was found to be both safe and well t olerated.32,33
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 25Trivalent RIVwas studied in a randomized trial study  of [ADDRESS_799354]- dose, egg -grown, quadrivalent -inactivated influenza 
vaccine for immunogenicity  and safet y. Quadrivalent RI V showed comparable safet y, 
tolerability
, and immunogenicity  to inactivated quadrivalent influenza vaccine .36
2.3.Benefit/Risk Assessment
More detailed information about the known and expected benefits and risks and reasonabl y 
expected AEs ofBNT162b2 (Omi XBB.1.5) /RIVmay be found in the combined IBs, which 
is the SRSD for this study . The SRSD for BNT162b2 (Omi XBB.1.5) and RI V is the 
Comirnaty®IBand Flublok Quadrivalent IB, respectively . Refer to the Study  Intervention(s) 
table in Section 6.1 for a complete description of SRSDs .
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 262.3.1. Risk Assessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Intervention(s): BNT162b2 (Om i XBB.1.5) /RIV administered together as a single injection or BNT162b2 (Omi XBB.1.5) and RIV administered 
simultaneously
Allergic reactions/ anaphylaxis may occur. Allergic reactions have been observed w ith an 
unknown frequency.Sites will have appropriate medication and
supportive measures for management of an acute 
hypersen sitivity reaction.
Local and systemic reactions to the vaccine may 
occur (injection site redness, injection site swelling, 
and injection site pain; fever, fatigue, headache, 
chills, vomiting, diarrhea, muscle pain, and joint 
pain) following vaccination.These are common adverse reactions seen with other 
vaccines,37as well as the COVID- [ADDRESS_799355] common events reported in a 
large -scale efficacy study with BNT162b2 
(C4591001) w ere mild to moderate pain at the 
injection site, fatigue, and headache.27The most 
common adverse reactions seen in a 
placebo -controlled safety and efficacy trial of RIV 
were local injection site pain, muscle aches, 
headache, and fatigue or lack of energy.[ADDRESS_799356] 
30 minutes after vaccination.
The safe ty profile of a novel vaccine is not yet fully 
characterized.BNT162b2 (Omi XBB1.5) /RIV is a novel 
combination ;however ,the individual active 
components from which it is made have been shown 
to have a positive benefit/risk profile.AE and SAE reports w illbe collected from the 
signing of the ICD through [ADDRESS_799357] 
30 minutes after vaccination.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 27Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Intervention(s): BNT162b2 (Om i XBB.1.5)
This vaccine has the same modRNA platform and 
LNP formulation as the original BNT162b2; 
therefore, the safety profile is expected to be similar 
to that of BNT162b2, ie, local reactions, such as 
injection site redness, injection site swelling, and 
injection site pain, and syste mic events, such as 
fever, fatigue, headache, chills, vomiting, diarrhea, 
muscle pain, and joint pain.
Other key risks identified for BNT162b2 are 
lymphadenopathy; hypersensitivity reactions, such 
as rash, pruritus, urticaria, angioedema, and 
anaphylaxis; and myocarditis and pericarditis.These are common adverse reactions seen with other 
vaccines as well as the COVID- 19 vaccine.
Data available from the C4591001 study 
(with BNT162b2) show ed low incidence of severe 
or serious events and no clinically conce rning safety 
observations across the safety population and within 
demographic subgroups based on age, sex, 
race/ethnicity, country, and baseline SARS -CoV -2 
status.27
Anaphylaxis: Frequency not known.
Myocarditis and pericarditis: Very rare cases of 
myocarditis and pericarditis have been reported 
following vaccination with modRNA SARS -CoV -[ADDRESS_799358]. Healthcare 
professionals should be ale rt to the signs and 
symptoms of myocarditis and pericarditis in vaccine 
recipi[INVESTIGATOR_840].
Postauthorization safety data surveillance has 
confirmed the safety profile observed in Study 
C4591001 and has resulted in identification of some 
additional adverse reactions (risks) as noted in the 
SRSD.Local reactions and systemic events will be recorded 
using a reactogenicity e -diary to monitor local 
reactions and systemic events in real time after 
vaccination.
AE and SAE reports w ill be collected from the 
signing of t he ICD through [ADDRESS_799359] a healthcare 
professional if a case is suspected.
For anaphylaxis, there is an on -site 30 -minute 
observation period after vaccination.
Instructions for handling suspected cases of 
myocarditis and pericarditis are found in 
Section 8.10.5 .
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 28Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Intervention(s): RIV (Flublok)
Local and systemic reactions to the vaccines may 
occur (injection site redness, injection site swelling, 
and injection site pain; fever, fatigue, headache, 
chills, vomiting, diarrhea, new or w orsened muscle 
pain, and new or w orsened joint pain) following 
vaccination.These are common reactions seen with other 
vaccines as well as RIV.33,37
Anaphylaxis : Frequency not known. 
GBS : The 1976 sw ine influenza vaccine was 
associated with an increased frequency of GBS. 
Evidence for a causal relation of GBS with other 
influenza vaccines is inconclusive; if an excess risk 
exists, it is probably slightly more than 1additional 
case per 1 million persons vaccinated. If GBS has 
occurred w ithin 6 weeks after receipt of a prior 
influenza vaccine, the decision to give Flublok 
should be based on careful consideration of the 
potential benefits and risks.33
Altered immunocompetence: If RIV is administered 
to immunocompromised individuals, including 
persons receiving immunosuppressive therapy, the 
immune response may be diminished.33
Limitations of 
vaccine effectiveness: Vaccination 
with RIV may not protect all vaccine recipi[INVESTIGATOR_840].33AE and SAE reports w ill be collected from the 
signing of the ICD through [ADDRESS_799360] 
30 minu tes after vaccination.
For anaphylaxis, there is an on -site 30 -minute
observation period after vaccination. 
Immunocompromised individuals and individuals 
receiving immunosuppressive therapi[INVESTIGATOR_603697] 1 and 2 of this study. 
Study Procedures 
Venipuncture will be performed during the study. There is the risk of bleeding, bruising, hematoma 
formation, and infection at the venipuncture site.Only appropriately qualified personnel will obtain 
the blood draw .
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 292.3.2. Benefit Assessment
SeeSection 2.3for overall study  risks. Benefits to individual participants enrolled in this 
study  may  be:
Receipt of an efficacious or potentially  efficacious COVID -19 vaccine.
Receipt of an efficacious or potentially  efficacious influenza vaccine.
Receipt of both a CO VID-19 vaccine and an influenza vaccine .
Contributing to research to help others.
2.3.3. Overall Benefit /Risk Conclusion
Taking into account the measures to minimize risk tostudy participants
, the potential risks 
identified in association with BNT162b2 (Omi XBB.1.5) /RIVare justified by  [CONTACT_603721] y participants.
3.OBJECTIVES, ENDPOINT S, AND ESTIMANDS
Objectives Endpoints Estimands
Prim ary: Prim ary: Prim ary: 
Safety
To describe the safety and 
tolerability of thestudy
interventionsLocal reactions (pain at the 
injection site, redness, and 
swelling) 
Systemic events (fever, 
fatigue, headache, chills, 
vomiting, diarrhea, new or 
worsened muscle pain, and 
new or w orsened joint pain)
AEs
SAEsThe percentage of participants 
receiving at least 1 dose of study 
intervention reporting:
Local reactions for up to 
7days following vaccination
Systemic events for up to 
7days following vaccination
AEs from vaccination 
through 4 weeks after 
vaccination
SAEs from vaccination 
through 6 months after 
vaccination
Immunogenicity
To describe the immune responses 
elicited by [CONTACT_214326]162b2 
(Omi XBB.1. 5)/RIV , BNT162b2 
(Omi XBB.1.5) + RIV
coadministered, and BNT162b2 
(Omi XBB.1.5) and RIV
administered alone (4 weeks after 
vaccination)SARS -CoV- 2 
Omicron (XBB.1.5) –neutralizing 
titersIn participants complying with the 
key protocol criteria (evaluable 
participants) :
GMTs before vaccination and 
at 4 weeks after vaccination 
GMFR from before 
vaccination to 4 w eeks after 
vaccination 
Percentage of participants 
with serorespons eaat 4 weeks 
after vaccination
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 30Objectives Endpoints Estimands
HAI titers against the seasonal 
strains recommended by [CONTACT_603722] 2023 -2024 
influenza seasonIn participants complying with the 
key protocol criteria (evaluable 
participants) :
GMTs before vaccination and 
at 4 w eeks after vaccination
GMFR sfrom before 
vaccination to 4 weeks after 
vaccination 
The percentage sof 
participants achieving HA I
seroconversio nbat 4 w eeks 
after vaccination 
The percentages of 
participants with HAI titers 
≥1:40 before vaccination and 
at 4 w eeks after vaccination
Exploratory: Exploratory: Exploratory:
To describe the immune responses 
elicited by [CONTACT_214326]162b2 
(Omi XBB.1.5) /RIV, BNT162b2 
(Omi XBB.1.5) + RIV 
coadministered, and BNT162b2 
(Omi XBB.1.5) and RIV 
administered alone (6 months
after vaccination)SARS -CoV- 2 
Omicron (XBB.1.5) –neutralizing 
titersIn participants complying with the 
key protocol criteria (evaluable 
participants):
GMTs before vaccination and 
at 6 months after vaccination 
GMFR from before 
vaccination to 6 months after 
vaccination 
Percentage of participants 
with seroresponseaat 
6months after vaccination
HAI titers against the seasonal 
strains recommended by [CONTACT_603722] 2023 -2024 
influenza seasonIn participants complying with the 
key protocol criteria (evaluable 
participants):
GMTs before vaccination and 
at 6 months after vaccination
GMFR sfrom before 
vaccination to 6 months after 
vaccination 
The percentages of 
participants achieving HA I
seroconversionbat 6 months 
after vaccination 
The percentages of 
participants with HAI tit ers 
≥1:40 before vaccination and 
at 6 months after vaccination
To describe the immune response 
to emerging variants (under 
monitoring, of interest, and/or of 
concern)SARS -CoV-2– neutralizing titers
and/or HAI titers for variants 
(under monitoring, of interest, 
and/or of concern) not already 
specified
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 31Objectives Endpoints Estimands
To descriptively compare the
immune responses between 
vaccine groupsSARS -CoV- 2 Omicron 
(XBB.1.5) –neutralizing titers and 
HAI titers for the seasonal strains 
recommended by [CONTACT_603723] 2023 -2024 
influenza season
a.Seroresponse is defined as achieving a ≥4-fold rise from baseline (before the study vaccination). If the 
baseline measurement is below the LLOQ, the postvaccination measure of ≥4 × LLOQ is considered 
seroresponse.
b.Seroconversio n is defined as an HAI titer 1:10 prior to vaccination and ≥ 1:[ADDRESS_799361], or an HAI titer of ≥1:[ADDRESS_799362].
4.STUDY DESIGN
4.1.Overall Design
This is a Phase 1/2 single -blind (site -and sponsor -unblinded) study  to evaluate the safet y, 
tolerability
, and immunogenicity  oflicensed BNT162b2 (Omi XBB.1.5) and RI V 
administered together asa single injection (referred to as BNT162b2 [Omi XBB.1.5]/ RIV) in 
healthy  adults 5 0 years of age or older. 
The safet y, tolerability , and immunogenicit y of BNT162b2 (OmiXBB1.5) /RIV administered 
asa single injection will be compared to BNT162b2 (Omi XBB.1.5) and RIV administered 
simultaneously  as 2 separate injections (coadministered), and to BNT162b2 (Omi XBB.1.5)
or RIV when administered alone. 
Across Phases1 and 2, approximately  640 participants in total will be randomized with an 
equal randomization ratio (1:1:1:1) to each of the following vac cine groups and stratified b y 
age group (50 through 64 y ears of age and ≥65 years of age) :  
Group 1: BNT162b2 (Omi XBB.1.5) /RIV (as a single injection) administered in the left 
deltoid and placebo administered in the right deltoid
Group 2: BNT162b2 (Omi X BB.1.5) 
administered in the left deltoid and RIV
administered in the right deltoid
Group 3: BNT162b2 (Omi XBB.1.5) administered in the left deltoid and placebo
administered in the right deltoid
Group 4: RIVadministered in the left deltoid and placebo administered in the right 
deltoid
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 32During Phase 1, a total of ~20 participants will be enrolled in each vaccine group. Enrollment 
of participants in each vaccine group will be controlled such that ~10 participants 50 through 
64 years of age (sentinel parti cipants, considered Phase 1a ) can be vaccinated in each of the 
groups on the first day . This will be monitored by  [CONTACT_456] , who will inform sites to pause 
enrollment once the target has been reached. Vaccination of the remaining ~40 participants
(
~10 pe r vaccine group) will commence no sooner than 24 hours after this safet y pause. The 
participants vaccinated after the safety  pause will be ≥65 years of age (considered Phase 1b).
Once ~
20participants per vaccine group have been vaccinated in Phase 1, the IRT s ystem 
will block any  further randomization, pending a review of at least 72 hours of safet y data for 
all participants b y the IRC. The outcome of the safety data review will be documented in a 
memo, which will be circulated to all sites prior to s tarting enrollment in Phase 2 . In Phase 2, 
140participants 50 years of age or older will be enrolled in each of the 4vaccine groups
(Table 2). Participants will be stratified by [CONTACT_551] , 50 through 64 years of age and 
≥65 years of age.
Table 2. Phase 1/2 Vaccine Group Summary
Vaccine Group 
NumberVaccine Group Description Phase 1a
(Number of 
Participants per 
Vaccine Grou p)Phase 2b
(Number of 
Participants per 
Vaccine Group)
1 BNT162b2 (Omi XBB.1.5) /RIV 
and placebo20 140
2 BNT162b2 (Omi XBB.1.5) and 
RIV20 140
3 BNT162b2 (Omi XBB.1.5) and 
placebo20 140
4 RIV and placebo 20 140
a.Phase 1 aparticipants will be 50 through 64 years of age at Visit 1 (Day 1). Phase 1b participants will be 
≥65 years of age at Visit 1 (Day 1).
b.Phase 2 participants will be 50 years of age or older at Visit 1 (Day 1).
Prespecified local reaction and sy stemic event data will be collected in an e -diary  during the 
7 day s, or longer for ongoing s ymptoms, after study  intervention (ie, from Day  1, the day  of 
vaccination, until sy mptom resolution), as well as any medication ta ken during this period to 
treat an y pain symptoms or fever . 
Blood samples of approximately  20 mL will be collected from all participants for 
immunogenicit y assessments prior to vaccination and at 4 weeks and 6 months after 
vaccination.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 33Following vaccinati on, AEs will be collected from informed consent signing through Visit 2
(approximately  4 weeks after vaccination), and SAEs will be collected from informed 
consent signing through Visit 3(approximately  6 months after vaccination). In addition, AEs 
occurri ng up to 48 hours after blood draws will also be collected.
4.2.Scientific Rationale for Study Design
The overall scientific rationale for the stud y design is presented in Section 2.1.
4.2.1.
Choice of Contraception/Barrier Requirements 
Human reproductive safety  data are not available for the RI Vused in this study , but there is 
no suspi[INVESTIGATOR_603698] y based on the intended pharmacology  of the 
compound. The use of a highl y effective method of contraception is required 
(see Appendix 4 ).
4.3.Justification for Dose
4.3.1. Monovalent BNT162b2 (Omi XBB.1.5)
The 30- μg dose level of BNT162b2 was shown to be effective and is licensed for use in the 
US.[ADDRESS_799363] iveand is licensed for use in the US.33
4.3.3.
BNT162b2 (Omi XBB.1.5)/ RIV
This will be a combination of BNT162b2 (Omi XBB.1.5) and RIV using the dose levels 
detailed in Section 4.3.[ADDRESS_799364] participan ts for whom participation in the study  is considered 
appropriate. All relevant medical and nonmedical conditions should be taken into 
consideration when deciding whether a particular participant is suitable for this protocol .
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 34Prospective approval of proto col deviations to recruitment and enrollment criteria ,also 
known as protocol waivers or exemptions, is not permitted .
Individual participants may  not be enrolled in this study  more than once.
Note: "Enrolled" means a participant's agreement to participate in a clinical study  following 
completion of the informed consent process and randomization.
5.1. Inclusion Criteria
Participants are eligible to be included in th isstudy  only  if all of the following criteria appl y:
Age and Sex :
1.Male or female p articipants aged 50years or older at Visit 1 (Day  1). 
Refer to Appendix 4 for reproductive criteria for male ( Section 10.4.1) and female 
(Section 10.4.2) participants .
Disease Characteristics:
Not applicable. 
Other Inclusion Criteria :
2.Participants who are willing and able to compl y with all scheduled visits, the 
investigational plan, laboratory  tests, lifest yle considerations, and other study  procedures.
3.Health y participants who are determined b y medical history, ph ysical examination 
(if required), and clinical judgment of the investigator to be eligible for inclusion in the 
study .
Note: Health y participants with preexisting stable disease, defined as dis ease not 
requiring significant change in therap y or hospi[INVESTIGATOR_76807] 6 weeks before enrollment, can be included. 
4.
Capable of giving signed informed consent as described in the protocol, which includes 
compliance with the req uirements and restrictions listed in the ICD and in this protocol.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 355.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Any medical or ps ychiatric condition including recent (within the pas t year) or active 
suicidal ideation /behavior or laboratory  abnormality  that may  increase the risk of study  
participation or ,
in the investig ator’s judgment ,make the participant inappropriate for the 
study .
2.Known infection with HIV, HCV, or HBV.
3.History  ofsevere adverse reaction associated with any  vaccine and/or severe allergic 
reaction (eg, anaph ylaxis) to any  component of the study  interventions.
4.Participants with a history of autoimmune disease or an active autoimmune disease 
requiring therapeutic inte rvention, including but not limited to sy stemic or cutaneous 
lupus ery thematosus, autoimmune arthritis/rheumatoid arthritis, multiple sclerosis, 
Sjögren’s s yndrome, idiopathic thrombocy topenia purpura, glomerulonephritis, 
autoimmune thy roiditis, temporal a rteritis, psoriasis, and/or insulin -dependent diabetes 
mellitus.
5. Immunocompromised individuals with known or suspected immunodeficiency, 
determined b y history  and/or laboratory /physical examination.
Note: I ndividuals who have had a splenectom y or have func tional asplenia will be 
considered ineligible.
6.Current heart disease, uncontrolled hy pertension, or a prior history  of m yocarditis or 
pericarditis.
Note: Hy pertension that has been controlled a minimum of 12 weeks, stable coronary  
artery  disease, and stab le mild valvular disease are not exclusionary .
7. Bleeding diathesis or condition associated with prolonged bleeding that would, in the 
opi[INVESTIGATOR_871], contraindicate intramuscular injection.
8. Women who are pregnant, plan to become pregnant during the study ,or are 
breastfeeding.
9.Prior history  of ischemic stroke or transient ischemic attack.
10.Prior history  of GBS.
11.Participants with a calculated BMI of ≥35.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 36Prior/Concomitant Therapy:
12.Receipt of chronic medications with known sy stemic immunosuppressant effects 
(including cy totoxic agents or sy stemic corticosteroids), or radiotherapy , within 60 day s 
before enrollment through conclusion of the study.
Note: Sy stemic corticosteroids are defined as those administered for ≥ 14 day s at a 
dose of ≥20 mg/day  of prednisone or equivalent (eg, for cancer or an autoimmune 
disease) or planned receipt throughout the stud y. Inhaled/nebulized, intra -articular, 
intrabursal, or topi[INVESTIGATOR_2855] (skin or ey es) corticosteroids are permitted.
13.Receipt of blood/plasma pr oducts, immunoglobulin, or monoclonal antibodies used for 
the treatment or prevention of COVID -19 or those that are considered 
immunosuppressive, from 90 days before study  intervention administration, or planned 
receipt throughout the study .
14.Vaccination wi th any  investigational or licensed influenza vaccine within 6months 
(180 days) before stud y intervention administration, or ongoing receipt of chronic 
antiviral therap y with activity  against influenza.
15.Vaccination with any  investigational or licensed COV ID-19 vaccine within 6months 
(180 days) before stud y intervention administration.
Prior/Concurrent Clinical Study Experience:
16.Participation in other studies involving administration of a ninvestigational product
within 28 day s prior to, and/or during, participation in this study .
Note: I n addition to administration of investigational products, study  interventions 
may include additional procedures, such as collection of biological samples. 
Therefore, participants may  not be in another study  whereby  [CONTACT_603724], such as 
respi[INVESTIGATOR_603693], may  interfere with compliance with this study ’s protocol.
Diagnostic Assessments:
Not applicable.
Other Exclusion Criteria
:
17.Investigator site staff directly  involved in the conduct of the study  and their family  
members, site staff otherwise supervised b y the investigator, and sponsor and sponsor 
delegate employ ees directly  involved in the conduct of the study  and their family  
members.
18.Deprived of freedom b y an administrative or court order, or in an emergency  setti ng, or 
hospi[INVESTIGATOR_29476].
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 3719. Current alcohol abuse or drug addiction that in the opi[INVESTIGATOR_2511] i nvestigator might 
interfere with the study  conduct or completion.
5.3.Lifestyle Considerations
5.3.1. Contraception 
The investigator or their designee, in consultation with the participant, will confirm that the 
participant is utilizing an appropriate method of contraception for the individual participant 
and their partner(s) from the permitted list of contraception methods (see Appendix 4 ,
Section 10.4.4) and will confirm that the participant has been instructed in its consistent and 
correct use. The investigator or design
ee will advise the participant to seek advice about the 
donation and cry opreservation of germ cells prior to the start of study  intervention, if 
applicable.
At time points indicated in the SoA, the investigator or designee will infor m the participant 
of the need to use acceptable effective contraception consistently  and correctly  and document 
the conversation and the participant ’s affirmation in the participant’s chart. P articipants need 
to affirm their consistent and correct use of a t least [ADDRESS_799365] the participant to call immediately  if the 
selected contraception method is discontinued and document the requirement to use an 
alternate protocol-specified method, including if the participant will n o longer use abstinence 
as the selected contraception method, or if pregnancy is known or suspected in the participant 
or partner .
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subs equently enrolled in the study . A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the CONSORT 
publishing requirements and to respond to queries from regulatory authorities. Minima l 
information includes demograph y, screen failure details, and an y SAE s.
Individuals who do not meet the criteria for participation in this study  (screen failure) may be 
rescreened under a different participant number, once eligibility  criteria are met.
5.5. Criteria for Temporarily Delaying Enrollment/Randomization/Administrat ionof 
Study Intervention 
The following conditions may  allow a participant to be randomized once the conditions have 
resolved and the participant is otherwise eligible . Participants mee ting these criteria at Visit 1 
will be considered screen failures if enrollment has closed once the condition(s) has/have 
resolved.
A positive influenza or SARS -CoV -[ADDRESS_799366] result (NAAT or rapid antigen test) within the 
previous 28 day s.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 38Current febrile illness (oral temperature ≥38.0°C [ ≥100.4°F]) or other acute illness within 
48 hours before study
 intervention administration.
Receipt of an y nonstud y vaccine within 28 day s before study  intervention administration 
at Visit 1.
Anticipated receipt of any nonstudy  vaccine within 28 day s after study  intervention 
administration at Visit 1.
Receipt of short -term ( 14 day s) systemic corticosteroids at a dose of ≥ 20 mg/day  of 
prednisone or equivalent. Study  intervention administration should be delay ed until 
systemic corticosteroid use has been discontinued for at least 28 day s.
Note: Sy stemic corticosteroids administered at a dose of 20 mg/day  of prednisone or 
equivalent are permitted. Inhaled/nebulized, intra-articular, intrabursal, or topi[INVESTIGATOR_2855] 
(skin or ey es) corticosteroids are permitted.
6.STUDY INTERVENTION(S ) AND CONCOMITANT TH ERAPY
Study  interventions are all prespecified investigational and medical devices, and other 
interventions (eg, surgical and behavioral), intended to be administered to the study  
participants during the study  conduct.
6.1.Study Intervention(s) Administered
Participants will be enrolled and randomized to each of the following vaccine groups: 
Group 1: BNT162b2 (Omi XBB.1.5) /RIV (as a single injection) administered in the left 
deltoid and pl acebo administered in the right deltoid
Group 2: BNT162b2 (Omi XBB.1.5) administered in the left deltoid and RIV 
administered in the right deltoid
Group 3: BNT162b2 (Omi XBB.1.5) administered in the left deltoid and placebo 
administered in the right deltoid
Group 4: RIV administered in the left deltoid and placebo administered in the right 
deltoid
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 39Study Intervention(s)
Intervention Name [CONTACT_214326]162b2 
(Omi XBB.1.5) /RIVBNT162b2 (Omi XBB.1.5) RIV Normal saline placebo
Type mRNA andrecom binant 
protein vaccine mRNA vaccine Recombinant protein vaccine Placebo
Use Experimental Com parator Com parator Placebo for blinding
IMP or NIMP/AxMP IMP IMP IMP IMP
Dose Form ulation Suspension for injection and 
Recombinant Suspension for injection Solution for injection Normal saline (0.9% sodium 
chloride solution for 
injection)
Unit Dose Strength(s) As detailed in the IP M As detailed in the IPM As detailed in the IPM N/A
Targeted Influenza Strains As recommended by [CONTACT_603725] -based vaccines 
(2023 -2024 northern 
hemisphere influenza 
season)aN/A As recommended by [CONTACT_603725] -based vaccines 
(2023 -2024 northern 
hemisphere influenza 
season)aN/A
Dosage Level(s) BNT162b2 (Omi XBB.1.5) 
30 µg
RIV 180 μg30 µg mRN A 180 μg R ecombinant protein 0.5mL
Route of Adm inistration Intramuscular injection Intramuscular injection Intramuscular injection Intramuscular injection
Sourcing Provided centrally by [CONTACT_603726]
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 40Study Intervention(s)
Packaging and Labeling Study intervention will be 
generated by [CONTACT_228005]- level combinations 
detailed below :
BNT162b2 
(Omi XBB.1.5)
RIV
Each vial will be labeled per 
country requirementStudy intervention will be 
provided in a glass vial as 
open -label supply. Each vial 
will be labeled per country 
requirementStudy intervention will be 
provided as either a PFS or a 
glass/plastic vial as 
open -label supplyStudy intervention will be 
provided in aplastic vial as 
open -label supply
SRSD Com bined IBs IB Flublok IB N/A
a.For the 2023 -2024 influenza season ,Flublok Quadrivalent is formulated to contain 180 µ g HA per 0.5 -mL dose, with 45 µg HA of each of the following 
4 influenza virus strains: A/West Virginia/30/2022 (A/Wisconsin/67/2022 pdm09 -like virus) (H1N1), A/Darwin/6/2021 (H3N2), 
B/Austria/1359417/2021 ,and B/Phuket/3073/2013.
Study Arm(s)
Group 1 2 3 4
Arm  Title BNT162b2 
(Omi XBB.1.5)/RIV + 
normal saline placeboBNT162b2 
(Omi XBB.1.5) + RIVBNT162b2 (Omi XBB.1.5) + 
normal saline placeboRIV + normal saline placebo
Arm  Description Participants will receive a 
single injection combination 
of BNT162b2 
(Omi XBB.1.5) (30µg) and 
RIV (180 µg)administered
in the left deltoid and normal 
saline plac ebo administered
in the right deltoid at Visit 1 
(Day 1)Participants will receive 
BNT162b2 (Omi XBB.1.5) 
(30 µg) administered in the 
left deltoid and RIV (180 µg) 
administered in the right 
deltoid at Visit 1 (Day 1)Participants will receive 
BNT162b2 (Omi XBB.1.5)
(30 µg) administered in the 
left deltoid and norm al saline 
placebo administered in the 
right deltoid at Visit 1 
(Day 1)Participants will receive RIV 
(180 µg) administered in the 
left deltoid and norm al saline 
placebo administered in the 
right de ltoid
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 416.1.1. Administration
Standard vaccination practices must be observed and vaccine must not be injected into blood 
vessels. Appropriate medication and other supportive measures for management of an acute 
hypersensitivity  reaction must be available in accordance with local guidelines for standard 
immunization practices.
Administration of study  interventions will be performed by  [CONTACT_240833], 
trained, and vaccine -experienced member of the study  staff (eg, ph ysician, nurse, phy sician’ s 
assistant, nurse practitioner, pharmacist, or medical assistant) as allowed by [CONTACT_5737], state, and 
institutional guidance. 
Study  intervention administration details will be recorded on the CRF .
Participants will receive [ADDRESS_799367]  as to ensure that the participants 
remain blinded.
Table 3. Anatomical Location for Study Intervention Administration
Vaccine Group Number Left DeltoidaRight Deltoida
1 BNT162b2 (Omi XBB.1.5) /RIV Placebo
2 BNT162b2 (Omi XBB.1.5) RIV
3 BNT162b2 (Omi XBB.1.5) Placebo
4 RIV Placebo
a.Study intervention will be administered in contralateral arms. Local reactions will be assessed at the 
injection site on both the left and right deltoid s.
6.1.2. Medical Devices 
RIV and normal saline placebo may  be provided as a PFS, in which case the PFS should be 
considered a medical device.
All medical device deficiencies (including malfunction, use error , and inadequate labeling) 
for the medical devices listed above shall be documented and reported by  [CONTACT_603727] (see Section 
8.4.9) and appropriatel y managed b y the 
sponsor .
6.2.Preparation , Handling , Storage , and Accountability
1.The investigator or designee must confirm that 
appropriate conditions (eg, temperature) 
have been maintained during transit for all study intervention sreceived and any  
discrepancies are reported and resolved before use of the study  intervention. 
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply , prepare, and/ or ad minister study  intervention. 
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 423.All study  intervention smust be stored in a secure, environmentally  controlled, and 
monitored (manual or automated recording ) area in accordance with the labeled storage 
conditions with access limited to the investigator and a uthorized site staff. At a minimum, 
daily  minimum and maximum temperatures for all site storage locations must be 
documented and available upon request. Data for nonworking day s must indicate the 
minimum and maximum temperatures since previously  documented upon return to 
business.
4.Any excursions from the study  intervention label storage conditions should be reported to 
[COMPANY_007] upon discovery  along with actions taken. The site should activel y pursue options 
for returning the stud y intervention to labeled stor age conditions, as soon as possible. 
Once an excursion is identified, the study  intervention must be quarantined and not used 
until [COMPANY_007] provides permission to use the study  intervention. Specific details regarding 
theexcursion definition and informatio n toreport for each excursion will be provided to 
the site in the I P
M.
5.Any storage conditions stated in the SRSD will be superseded by  [CONTACT_214341]. See the I PM for storage conditions of the study  intervention.
6.Study  interven tions should be stored in their original containers.
7. The investigator, institution, head of the medical institution (where applicable), or 
authorized site staff is responsible for study  intervention accountability , reconciliation, 
and record maintenance (ie, receipt, reconciliation, and final disposition records) , such as 
the IPAL or sponsor -approved equivalent . All study  intervention s will be accounted for 
using a study  intervention accountabilit y form/record. 
8.Further guidance and information for the fi nal disposition of unused study  interventions 
are provided in the I PM. All destruction must be adequately documented. If destruction is 
authorized to take place at the investigator site, the investigator must ensure that the 
materials are destro yed in comp liance with applicable environmental regulations, 
institutional policy , and any  special instructions provided by  [CONTACT_4618].
Upon identification of a product complaint, notify the sponsor w ithin 1 business day  of 
discovery  as described in the I PM.
6.2.1. Preparation and Dispensing
See the IPM, package insert, or equivalent for instructions on how to prepare the study  
intervention for administration. Study  intervention should be prepared and dispensed by  [CONTACT_160440] y qualified and experienced member of the study  staff (eg, phy sician, nurse, 
physician’s assistant, nurse practitioner, pharmacy assistant/technician, or pharmacist) as 
allowed b y local, state, and institutional guidance. A second staff member will verify  the 
dispensing.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 436.3.Assignment to Study Intervention
Allocation (randomization) of participants to study  arms will proceed through the use of an 
IRT s ystem (I WR). The site personnel (study  coordinator or specified designee) will be 
required to enter or select information including but not limited to the user ’s ID and 
password, the protocol number, and the participant number. The site personnel will then be 
provided with a randomization number corresponding to the assigned study intervention.* 
The I RT sy stem will provide a confirmation report containing the participant number, 
randomization number, and study  intervention allocation assigned. Confirmation report must 
be stored in the site’s files.
* Do not randomize until eligibility  is confirmed and the participant is present.
Study  intervention will be dispensed at the stud y visits summarized in the SoA. 
The study -specific I RT reference manual and I PMwill provide the contact [CONTACT_185603] I RT sy stem.
6.4.Blinding
This is a single -blind study . 
6.4.1. Blinding of Participants
Participants will be blinded to their assigned study intervention.
6.4.2. Blinding of Site Personnel
Investigators and other site staff will be unblinded to participants’ assigned study  
intervention. 
6.4.3. Blinding of the Sponsor
Sponsor staff will be un blinded to participants’ assigned study  intervention. 
6.4.4. Breaking the Blind 
Not applicable .
6.5. Study Intervention Compliance
When participants are dosed at the site, they  will receive study  intervention directly  from the 
investigator or designee, under medic al supervision. The date and time of each dose 
administered in the clinic will be recorded in the source documents and recorded in the CRF. 
The dose of stud y intervention and study participant identification will be confirmed at the 
time of dosing b y a mem ber of the stud y site staff other than the person administering the 
study  intervention.
6.6. Dose Modification
Not applicable.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 446.7.Continued Access to Study Intervention A fter the End of the Study
No study  intervention will be provided to participants at the end of their study  participation.
6.8.Treatment of Overdose
For this study , any  dose of study  intervention greater than 1 dose of study  intervention within 
a 24-
hour time period will be considered an overdos e.
[COMPANY_007] does not recommend specific treatment for an overdose.
In the event of an overdose, the investigator should:
1.Contact [CONTACT_219876] 24 hours.
2.Closely  monitor the participant for an y AEs/SAEs as medicall y appropriate and follow up 
until resolution, stabilization, the event is otherwise explained, or the participant is lost to 
follow -up (as defined in Section 7.3). 
3.Document the quantit y of the excess dose as well as the duration of the overdose in the 
CRF.
4.Overdose is reportable to [COMPANY_007] Safety  only when associated with an SAE .
6.9.Prior and Concomitant Therapy
The following concomitant medications and vaccinations will be recorded in the CRF:
Receipt of an y COV ID-[ADDRESS_799368] visit 
(Visit 3).
Receipt of licensed or investigational influenza vaccine from [ADDRESS_799369] visit (Visit 3).
Any vaccinations received from [ADDRESS_799370] visit (Visit 
3).
Details of an y concomitant medication taken to treat fever or pain (solicited 
reactogenicity  symptoms )asreported in the e -diary  will be collected.
6.9.1. Prohibited During the Study
Receipt of the following vaccines and medications during the time periods listed below may  
exclude a participant from the per- protocol anal ysis from that point onward; however, it is 
anticipated that the participant would not be withdrawn from the study  (see Section 7). 
Medications should not be withheld if required for a participant’s medical care.
Unless considered medically  necessary , no vaccines other than study  intervention should 
be administered with in 14 day s before and 14 days after study  vaccination at Visit 1.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 45Receipt of an y other (nonstudy ) coronavirus vaccine from enrollment throughout the 
entire study  is prohibited.
Receipt of an y other (nonstudy ) seasonal influenza vaccine from enrollment thro ughout 
the entire stud y is prohibited.
Receipt of chronic medications with known sy stemic immunosuppressant effects, or 
radiotherap y, within 60 days before enrollment through conclusion of the study is 
prohibited.
Receipt of s ystemic corticosteroids (≥20 m g/day  of prednisone or equivalent) for 
≥14 day s is prohibited from 28 day s prior to enrollment through 28 day s after 
administration of the study  intervention.
Planned r eceipt of blood/plasma products, immunoglobulins, or monoclonal antibodies, 
from 90days before study  intervention administration through conclusion of the study , is 
prohibited.
Prophy lactic antipy retics and other pain medication to prevent s ymptoms associated with 
study  intervention administration are not permitted. However, if a participan t is taking a 
medication for another condition, even if it may  have antipy retic or pain -relieving 
properties, it should not be withheld prior to study vaccination.
6.9.2. Permitted During the Study
Hormonal contraceptives that meet the requirements of this study  are allowed to be used 
in participants who are WOCBP (see Appendix 4).
Medication other than that described as prohibited in Section 6.9.1 required for treatment 
of preexisting conditions or acute illness is permitted.
Inhaled, topi[INVESTIGATOR_2855], or localized injections of corticosteroids (eg, intra -articular or intrabursal 
administration) are permitted.
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
It may  be necessary  for a participant to permanently  discontinue study  intervention .Reasons 
for permanent discontinuation of study  intervention include the following : AEs; participant 
request; investigator request; pregnancy
; protocol deviation (including no longer meeting all 
the inclusion criteria, or meeting 1 or more exclusion criteria).
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 46Discontinuation o f study  intervention does not represent withdrawal from the study . If study  
intervention is permanently discontinued, the participant should remain in the study  to be 
evaluated for safet
y.See the SoA for data to be collected at the time of discontinuation of 
study  intervention and follow -up for an y further evaluations that need to be completed.
In the event of discontinuation of study  intervention, it must be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further 
receipt of stud y intervention or also from study  procedures, further study  follow -up, and/or 
future collection of additional information.
7.2.Participant Discontinuation/ Withdrawal F rom the Study
A participant may  withdraw from the study  at an y time at theirown request . Reasons for 
discontinuation from the study  include the following :
Refused further stud y procedures;
Lost to follow -up;
Death;
Study  terminated by  [CONTACT_3211];
Reactogenicit y event;
AEs;
Participant request; 
Investigator request;
Select protocol deviations (eg, receipt of a COVID -19 and influenza vaccine at an y time 
during this study ).
If a participant withdraws from the study , they may request destruction of any  remaining 
samples taken and not tested
,andtheinvestigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
If the participant withdraws from the study  and also withdraws consent ( seeSection 7.2.1)
for disclosure of future information, no further evaluations will be performed and no 
additional data will be collected. The sponsor may retain and continue to use an y data 
collected before such withdrawal of consent.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 477.2.1. Withdrawal of Consent 
Participant s who request to discontinue receipt of study  intervention will remain in the study  
and must continue to be followed for protocol -specified follow -up procedures. The onl y 
exception to this is when a participant specificall y withdraws consent for any  further contact 
[CONTACT_185609]. 
Participant s should notify  the investigator in writing of the decision to withdraw consent 
from future follow -
up, whenever possible. The withdrawal of consent should be explained in 
detail in the medical records by  [CONTACT_093], as to whether the withdrawal is only  from 
further receipt of study  intervention or also from study  procedures and/or post vaccination
study  follow -up, and entered on the appropriate CRF page. In the event that vital status 
(whether the participant is alive or dead) is being measured, publicl y available information 
should be used to determine vital status only  as appropriatel y directed in accordance with 
local law .
7.3.Lost to Fol low-Up 
A participant will be considered lost to follow -up if the participant repeatedly  fails to return 
for scheduled visits and is unable to be contact[CONTACT_17066].
The following actions must be taken if a participant fails to attend a required study  visit:
The site must attempt to contact [CONTACT_46342] . Counsel the participant on the importance of maintaining the assigned visit 
schedule ,and ascertain whether the participant wishes to and/or should continue in the 
study ;
Before a participant is deemed lost to follow- up, the investigator or designee must make 
every  effort to regain cont act with the participant (where possible, 3 telephone calls and, 
if necessary , a certified letter to the participant’s last known mailing address or local 
equivalent methods). These contact [CONTACT_13140]’s 
medical record ;
Should the participant continue to be unreachable, the participant will be considered to 
have withdrawn from the study . 
8.STUDY ASSESSMENTS AN
D PROCEDURES
8.1.Administrative Procedures
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing any  study -specific procedures.  
Age will be collected to critically  evaluate the immune response and safety  profile by  [CONTACT_654].
Study  procedures and their timing are summarized in the SoA.Protocol waivers or 
exemptions are not allowed.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 48Adherence to the stud y design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
Every ef fort should be made to ensure that protocol -required tests and procedures are 
completed as described. However , it is anticipated that from time to time there may  be 
circumstances outside the control of the investigator that make it unfeasible to perform th e 
test. I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the participant. When a protocol -required test cannot be performed, the 
investigator will document the reason for the missed test and an y correcti ve and preventive 
actions that they have taken to ensure that required processes are adhered to as soon as 
possible. The study  team must be informed of these incidents in a timely  manner .
For samples being collected and shipped, detailed collection, proces sing, storage, and 
shipment instructions and contact [CONTACT_19987] .
The total blood sampling volume for individual participants in this study  is approximately  
60mL The actual collection times of blood sampling may  change. Additional blood samples 
may be taken for safet y assessments at times specified by [CONTACT_4618] , provided the total volume 
taken during the stud y does not exceed [ADDRESS_799371] data points. Telehealth 
includes the exchange of healthcare information and services via telecommunication 
technologies (eg, audio, video, videoconferencing software) remotel y, allowing the 
participant and the investigator to communicate on aspects of clinical care, including medical 
advice, reminders, education, and safet y monitoring. Assessments that may  be performed 
during a telehealth visit are described in the SoA.
Study  participants must be reminded to promptl ynotify site staff about an y change in their 
health status.
8.2.
Efficacy and/or Immunogenicity Assessments
Samples will be collected at the time points specified in the SoA from al l participants and the 
following assay s will be performed:
SARS -CoV -2 neutralization assay s (Omi XBB.1.5).
HAI titers (from HAI based on cell -derived virus) for the seasonal strains (2×A, 2×B) 
recommended b y WHO.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 49To describe the immune response to emerging variants of SARS -CoV-2 and/or influenza , 
additional assay  may  be run on an exploratory  basis. 
Virus microneutralization assay s may  be run on all or a subset of samples on an exploratory  
basis as detailed in the SAP.
8.2.1. Testing for SARS -CoV -[ADDRESS_799372] testing the samples will not know the participant’s 
identity, study  visit, or study  cohort associated with the sample. Samples that remain after 
performing assays outlined in the protocol may be stored by  [CONTACT_4618]. Unless a time limitation 
is requir ed by [CONTACT_240846], the samples will be stored for up to 
15 years after the end of the study  and then destroyed. If allowed by  [CONTACT_48355], stored samples 
may be used for additional testing to better understand the immune responses to the 
vaccine(s) under study  in this protocol, to inform the development of other vaccines or 
vaccine -related products, and/or for vaccine -related assay  work supporting vaccine programs.
No testing of the participant’s DNA will be performed.
The partici pant may  request that their samples, if still identifiable, be destroy ed at any  time; 
however, an y data already collected from those samples will still be used for this research. 
The biological samples may  be shared with other researchers as long as confidentiality  is 
maintained and no testing of the participant’s DNA is performed.
8.3.Safety Assessments
Planned time points for all safety  assessments are provided in the SoA.Unscheduled safet y 
measurements may  be obtained at any  time during the study  to assess any  perceived safety  
issues.
8.3.1. Physical Examinations
In this stud y, a ph ysical examination may  be performed prior to vaccination, if clinically  
indicated .
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 50Physical examination findings collected during the study  will be considered source record 
and will not be required to be reported , unless otherwise noted. Any untoward ph ysical 
examination findings that are identified during the active collection period and meet the 
definition of an AE or SAE (Appendix 3 ) must be reported according to the processes in 
Sections 8.4.1 to8.4.3.
8.3.2. Vital Signs
For this study , the participant
’s oral temperature , pulse rate, and seated blood pressure will be 
measured prior to vaccination. Additionally , weight and height will be measured prior to 
vaccination.
Vital sign findings collected during the stud y will be considered source record and will not be 
required to be reported, unless otherwise noted.
Any untoward vital sign findings that are identified during the active collection period and 
meet the definition of an AE or SAE ( Appendix 3 ) must be reported according to the 
processes in Sections 8.4.1 to8.4.3.
8.3.3. Clinical Safety Laboratory Assessments
Clinical safety  laboratory assessments will not be collected in this study . 
8.3.4. Electronic Diary
All participants will be required to complete a reactogenicit y e-diary  after vaccination given 
at Visit 1, through an application installed on a provisioned devic e or on the participant
’s 
own personal device. All participants will be asked to monitor and record local reactions, 
systemic events, and use of an y medication for solicited pain symptoms or fever for 7 day s, 
or longer for ongoing s
ymptoms, from the day of administration of the study  intervention 
given at V isit1. The reactogenicit y e-diary  allows recording of these assessments each day , 
thus providing the accurate representation of the participant’s experience. Data on local 
reactions and s ystemic events r eported in the reactogenicit y e-diary  will be transferred 
electronically  to a third- party  vendor , where they  will be available for review by  [CONTACT_603728] -based portal.
At intervals agreed to b y the ve ndor and [COMPANY_007] , these data will be transferred electronicall y 
into [COMPANY_007] ’s database for anal ysis and reporting. Generally , these data do not need to be 
reported b y the investigator in the CRF as AEs. However, if a participant has a serious 
adverse event reported in the e -diary , the event(s) should be recorded on the CRF , regardless 
of whether the investigator considers the event(s) to be related . If a participant missed 
reporting an event in the e -diary  and reports it to the study  site instead, the event should also 
be recorded on the CRF .
Investigators (or designee) will be required to review the reactogenicity  e-diary  data online at 
frequent intervals to evaluate participant compliance and as part of the ongoing safet y review .
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 51The investigator or designee must obtain stop dates from the participant for any  symptoms 
ongoing on the last day  from Day  7 onwards and follow updaily  until resolution. The stop 
dates should be documented in the source documents and the information enter ed in the CRF .
[IP_ADDRESS]. Grading Scales
The grading scales used in this study  to assess local reactions and sy
stemic events as 
described below are derived from the FDA  CBER guidelines on toxicity  grading scales for 
healthy  adult volunteers enrolled in preventive vaccine clinical trials.37
[IP_ADDRESS]. Local Reactions
During the reactogenicit y e-diary  reporting period, participants will be asked to assess 
redness, swelling, and pain at each injection site and to record the s ymptoms in the 
reactogenicity  e-diary . 
If a local reaction persists bey ond the end of the 7- day e-diary  collection period following 
vaccination, the participant will be requested to report that information and/or an y new 
reactogenicity  reactions that develop to the investigator or the study  staff. The investigator 
will enter this additional information in the CRF .
Participants will be provided with a measuring device. Redness and swelling will be 
measured and recorde d in measuring device units (range: 1 to 21) and then categorized 
during anal ysis as absent, mild, moderate, or severe based on the grading scale in Table 4. 
Measurin g device units can be converted to centimeters according to the following formula: 
1 measuring device unit = 0.[ADDRESS_799373] 
should occur to ascertain further details and determine whether a site visit is clinically  
indicated. Onl y an investigator or medicall y qualified person is able to classify a participant ’s 
local reaction as Grade 4. If a participant experiences a confirmed Grade [ADDRESS_799374] immediately  notify  the s ponsor .
Table 4. Local Reaction Grading Scale
Mild
(Grade 1)Moderate
(Grade 2)Severe
(Grade 3)Potentially 
Life-Threatening
(Grade 4)
Pain at the 
injection siteDoes not interfere 
with activityInterferes with 
activityPrevents daily 
activityEmergency room 
visit or 
hospi[INVESTIGATOR_214308] 2.0cm to 5.0 cm
(5 to 10 measuring 
device units)5.0cm to 10.0 cm 
(11to 
20measuring 
device units)10cm 
(≥21measuring 
device units)Necrosis or 
exfoliative 
dermatitis
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 52Table 4. Local Reaction Grading Scale
Mild
(Grade 1)Moderate
(Grade 2)Severe
(Grade 3)Potentially 
Life-Threatening
(Grade 4)
Swelling 2.0cm to 5.0 cm
(5 to 10 measuring 
device units)5.0cm to 10.0 cm 
(11to 
20measuring 
device units)10cm 
(≥21measuring 
device units)Necrosis
[IP_ADDRESS]. Systemic Events
During the reactogenicit y e-diary  reporting period, participants will be asked to assess 
vomiting, diarrhea, headache, fatigue, chills, new or worsened muscle pain, and new or 
worsened joint pain and to record the s ymptoms in the reactogenicit y e-diary . The s ymptoms 
will be assessed b y the participant as absent, mild, mod erate, or severe according to the 
grading scale in Table 5.
If a s ystemic event persists bey ond the end of the 7 -day e
-diary  collection period following 
vaccination, the participant will be requested to report that information and/or any  new 
reactogenicity  events that develop to the investigator or the study  staff. The investigator will 
enter this additional information in the CRF .If a Grade [ADDRESS_799375] should occur to ascertain further details and 
determine whether a site visit is clinically  indicated. Only  an investigator or medicall y 
qualified person is able to classify  a participant ’s systemic even t as Grade 4. If a participant 
experiences a confirmed Grade [ADDRESS_799376] immediatel y notify 
the sponsor. A Grade 4 s ystemic event will be collected on the CRF .
Table 5. Systemic Event Grading Scale
Mild
(Grade 1)Moderate
(Grade 2)Severe
(Grade 3)Potentially 
Life-Threatening
(Grade 4)
Vom iting 1-2 times in 24 
hours2 times in 24 
hoursRequires IV 
hydrationEmergency room 
visit or 
hospi[INVESTIGATOR_106318] 2 to 3 loose stools 
in 24 hours4 to 5 loose stools 
in 24 hours6 or more loose 
stools in 24 hoursEmergency room 
visit or 
hospi[INVESTIGATOR_603699]/tiredness Does not interfere 
with activitySome interference 
with activityPrevents daily 
routine activityEmergency room 
visit or 
hospi[INVESTIGATOR_603700]
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 53Table 5. Systemic Event Grading Scale
Mild
(Grade 1)Moderate
(Grade 2)Severe
(Grade 3)Potentially 
Life-Threatening
(Grade 4)
Chills Does not inte rfere 
with activitySome interference 
with activityPrevents daily 
routine activityEmergency room 
visit or 
hospi[INVESTIGATOR_603701] w orsened 
muscle painDoes not interfere 
with activitySome interference 
with activityPrevents daily 
routine activityEmergency room 
visit or 
hospi[INVESTIGATOR_214311] w or 
worsened muscle 
pain
New  or w orsened 
joint painDoes not interfere 
with activitySome interference 
with activityPrevents daily 
routine activityEmergency room 
visit or 
hospi[INVESTIGATOR_603702] w or 
worsened joint pain
[IP_ADDRESS]. Fever
In order to record information on fever , a thermometer will be given to participants with 
instructions on how to measure oral temperature at home. Temperature will be collected in 
the reactogenicit y e-diary daily  for 7 day s or longer following vaccination (where Day  1 is 
the day  of vaccination). It will also be collected at any  time during the reactogenicity  e-diary  
data collection periods when fever is suspected. Fever is defined as an oral temperature 
≥38.0°C (≥100.4 °F). The highest temperature for each day will be recorded in the 
reactogenicity  e-diary . Temperature will be measured and recorded to [ADDRESS_799377]. 
Temperatures recorded in degrees Fahrenheit will be programmatically  converted to degrees 
Celsius and then categorized according to the scale shown in Table 6during anal ysis.
If a fever of 
≥39.0°C (≥102.1°F) is reported in the reactogenicity  e-diary , a telephone contact 
[CONTACT_214345] a site visit is clinically  
indicated. Onl y an investigator or medicall y qualified person is able to confirm a 
participant ’s fever as >40.0°C (>104.0°F). If a participant experiences a confirmed fever 
>40.0°C (>104.0°F), the investigator must immediately  notify  the spons or. Fevers >40.0°C 
(>104.0°F) will be collected on the CRF
.
Table 6. Scale for Fever
≥38.0-38.4°C (100.4 -101.1°F)
>38.4 -38.9°C (101.2 -102.0°F)
>38.9 -40.0°C (102.1 -104.0°F)
>40.0°C (>104.0°F)
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page [IP_ADDRESS]. Antipyretic Medication
The use of antipy retic medication sto treat pain sy mptoms or fever associated with study  
intervention administration will be recorded in the reactogenicit y e-diary  daily  during the 
7-day reporting period or longer for ongoing s ymptoms.
8.3.5. Phase [ADDRESS_799378] dose of study  intervention in Phase 1, whichever is later. These data 
will be monitored on an ongoing basis b y the investigator (or medicall
y qualified designee) 
and sponsor in order to promptly  identify  and flag any  event that potentially  contributes to a 
stoppi[INVESTIGATOR_1877].
The sponsor study  team will be unbli nded so will be able to assess whether or not a stoppi[INVESTIGATOR_603703] a participant’ s individual study  intervention allocation.
In the event that sponsor personnel confirm that a stoppi[INVESTIGATOR_4081], the following actions 
will commenc e:
The I RC will review all appropriate data.
The stoppi[INVESTIGATOR_603704].
For all participants vaccinated, all other routine study  conduct activities, including 
ongoing dat a entry , reporting of AEs, participant reactogenicity  e-diary  completion, 
blood sample collection, and participant follow -up, will continue during the pause.
A stoppi[INVESTIGATOR_603705]. Reactogenicity  e-diary  data confirmed by  [CONTACT_603729] a stoppi[INVESTIGATOR_1877]. Once the IRC have 
reviewed the safety  data and provided guidance, a notification will be sent from t he sponsor 
to the sites with guidance on how to proceed.
Stoppi[INVESTIGATOR_603706]:
If any vaccinated participant develops an SAE that is assessed b y the investigator as 
possibly  related to the study  intervention, or for which there is no alternative, plausible, 
attributable cause.
If any participant develops a Grade 4 local reaction or systemic event after vaccination 
(see Section 8.3.4) that is assessed as possibl y related by [CONTACT_093], or for which 
there is no alternative, plausi ble, attributable cause.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 55If any participant develops a fever >40°C (>104.0°F) for at least 1 dail y measurement 
after vaccination (seeSection [IP_ADDRESS]) that is assessed as possib ly related by  [CONTACT_298956], or for which there is no alternative, plausible, attributable cause. 
If any vaccinated participant develops confirmed my ocarditis or pericarditis.
If any vaccinated participant dies.
Ifany
vaccinated participant experience s a Grade 4 unsolicited AE, or SAE of any  
severit y, assessed as related to the study intervention by [CONTACT_093].
If any 2 participants vaccinated participants develop the same or similar Grade 3 or 
higher unsolicited AE, other than m yocarditis/perica rditis, assessed as related to study  
intervention by  [CONTACT_093]. Note that the solicited local reactions, sy stemic events, 
and fever specified in Section 8.3.4, reported within [ADDRESS_799379] 25 mIU/mL. Pregnancy  tests will be performed in WOCBP  at the times listed in 
theSoA, immediately  before the administration of each dose of study  intervention . A 
negative pregnancy  test result will be required prior to receiving the study  intervention . 
Pregnancy  tests may  also be repeated if requested by  [CONTACT_1202]/ECs or if required by  [CONTACT_13125]. In the case of a positive confirmed pregnancy , the 
participant will be withdrawn 
from administration of study  intervention but may remain in the study .
8.4.Adver se Events ,Serious Adverse Events , and Other Safety Reporting
The definitions of an AE and an SAE can be found in Appendix 3 .
AEs may  arise from s ymptoms or other complaints reported to the investigator by  [CONTACT_2416] (or , when appropriate, by  a caregiver , surrogate, or the participant's legall y 
authorized representative), or they  may  arise from clinical findings of the i nvestigator or 
other healthcare providers (clinical signs, test results, etc).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to purs ue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
the study  (see Section 7.1 ). 
During the active collection period as described in Section 8.4.1, e ach participant will be 
questioned about the occurrence of AEs in a nonleading manner .
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 56In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain specific follow -up 
information in an expedited fashion.
8.4.1. Time Period and Frequency for C ollecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“ active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant ’s participation in the study  (ie, before undergoing 
any study -related procedure and/or receiving study  intervention ), through and including 
Visit2.At Visit 3 (approximately  6 months after vaccination) ,the participant will b easked 
about AESI s 
since Visit 1.
Additionally , any AEs occurring up to [ADDRESS_799380] be 
recorded in the CRF.
SAEs will be collected from the time the participant provides informed consent through the 
duration of the study (Visit 3 , approximately  6 months after vaccination ).
Follow -up by  [CONTACT_185615] a level acceptable to the investigator .
When a clinically important AE remains ongoing at the end of the active collection period, 
follow -up by  [CONTACT_227985] a level acceptable to the investigator and [COMPANY_007] concurs with that assessment.
For participants who are screen failures, the active collection period ends when screen failure 
status is determined.
If the participant withdraws from the study and also withdraws consent for the collection of 
future information, the active collection perio d ends when consent is withdrawn.
If a participant permanently discontinues or temporaril y discontinues from the study  because 
ofan AE or SAE, the AE or SAE must be recorded on the CRF and the SAE reported using 
the Vaccine SAE Report Form or via PSSA.
Investigators are not obligated to activel y seek information on AEsor SAE safter the 
participant has concluded study  participation. However , if the investigator learns of any  SAE, 
including a death, at an y time after a participant has concluded stud y part icipation , and they  
consider the event to be reasonabl y related to the study  intervention, the investigator must 
promptly  report the SAE to [COMPANY_007] using the Vaccine SAE Report Form orvia PSSA .
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page [IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period as described in
Section 8.4.1 are report e d to [COMPANY_007] Safety  on the Vaccine SAE Report Form/PSSA
immediately  upon awareness and under no circumstance should this exceed 24 hours, as 
indicated in Appendix 3. The investigator will submit any updated SAE data to the sponsor 
within 24 hours of it sbeing available.
[IP_ADDRESS]. Recordi ng Nonserious AEs and SAEs on the CRF
All nonserious 
AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.4.[ADDRESS_799381] 
in the determination of case seriousness, further information may  be requested from the 
investigator to provide clarity  and understanding of the event in the context of the clinical 
study .
8.4.2. Method of Detecting AE s and SAEs
The method of recording, evaluating, and assessing causality  of AEs and SAE sand the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 .
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.4.3. Follow -Up of A Es and SAEs
After the initial AEor SAE report, the investigator is required to proactively  follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in suf ficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality . Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided. In the case of a participant death, a summary  of available 
autopsy  findings must be submitted as soon as possible to [COMPANY_007] Safety . 
Further information on follow -up procedures is provided in Appendix 3.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 588.4.4. Regulatory Reporting Requirements for SAEs
Prompt notification by  [CONTACT_11012] a n SAE is essential so that legal 
obligations and ethical responsibilities toward the safet y of participants and the safet y of a 
study  intervention und er clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with countr y-specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ECs, and investigators.
Investigator safety  reports must be prepared for S[LOCATION_003]R saccording to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary.
An investigator who receives S[LOCATION_003]R sor other specific safety information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD (s) for the 
study and will notify  the IRB/EC, if appropriate according to local requirements.
8.4.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and 
Occupational Exposure
Environmental exposure occurs when a person not enrolled in the study as a participan t 
receives unplanned direct contact [CONTACT_78261]. Such exposure 
may or may  not lead to the occurrence of an AE or SAE. Persons at risk for environmental 
exposure include healthcare providers, family members, and others who may be exposed . An 
environmental exp osure may include EDP, EDB , and occupational exposure.
Any such exposure s to the study  interventio nunder study  are reportable to [COMPANY_007] Safety  
within 24 hours of investigator awareness.
[IP_ADDRESS]. Exposure During Pregnancy
An EDP  occurs if:
A female participant is found to be pregnant while receiving or after discontinuing study 
intervention .
A male participant who is receiving or has discontinued study  intervention inseminates a 
female partner .
A female 
nonparticipant is found to be pregnant while being exposed or having been 
exposed to study  intervention because of environmental exposure. Below are examples of 
environmental EDP :  
A female family  member or healthcare provider reports that she is pregnant after 
having been expos
ed to the study  intervention by  [CONTACT_19991].
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 59A male famil y member or healthcare provider who has been exposed to the study  
intervention by  [CONTACT_603730].
The investigator must report EDP  to [COMPANY_007] Safety within 24 hours of the investigator ’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery  (see below for information related to 
termination of pregnancy). 
If EDP occurs in a participant /participant’s partner, the investigator must report this 
information to 
[COMPANY_007] Safety using the Vaccine SAE Report Form and an EDP 
Supplemental Form orvia PSSA , regardless of whether an SAE has occurred. Details of 
the pregnancy  will be collected after the start of study  intervention and until 28 day s after 
study  intervention.
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to [COMPANY_007] Safety  using the Vaccine SAE Report Form andanEDP 
Supplemental Form or via PSSA . Since the exposure information does not pertain to the 
participant enrolled in the study , the information is not recorded on a CRF; however, a 
copy  of the completed
report is maintained in the investigator site file.
Follow -up is conducted to obtain general information on the pregnancy  and its outcome 
for all EDP reports with an unknown outcome. The investigator will follow the 
pregnancy  until completion (or until pregnancy  termination) and notify  [COMPANY_007] Safet y of 
the outcome as a follow- up to the initial report . In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth. In the event of a termination, 
the reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
Abnormal pregnancy  outcomes are considered SAEs. If the outcome of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y), the investigator should follow the procedures 
for reporting SAEs. Additional information about pregnancy  outcomes that are reported to 
[COMPANY_007] Safety  as SAEs follows: 
Spontaneous abortion includ ingmiscarriage and missed abortion should be reported as an 
SAE ;
Neonatal deaths that occur within [ADDRESS_799382] to 
causality , as SAEs. In addition, infant deaths after 1 month should be reported as SAEs 
when the investigator assesses the infant death as related or possibly  related to exposure 
to the study  intervention. 
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 60Additional information regarding the EDP  may  be requested by  [CONTACT_456] . Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner .
[IP_ADDRESS]. Exposure During Breastfeeding
An EDB occurs if:
A female participant is found to be breastfeeding while receiving or after discontinuing 
study  intervention .
A female nonparticipant is found to be breastfeeding while being exposed or having been 
exposed to study  intervention (ie, environmental e xposure). An example of 
environmental EDB is a female famil y member or healthcare provider who reports that 
she is breastfeeding after having been exposed to the study  intervention by[CONTACT_603731] .  
The investigator must report EDB to [COMPANY_007] Safety  within 24 hours of the investigator ’s 
awareness, irrespective of whether an SAE has occurred. The information must be reported 
using the 
Vaccine SAE Report Form orvia PSSA . When EDB occurs in the setting of 
environmental exposure, the exposure information does not pertain to the participant enrolled 
in the study , so the information is not recorded on a CRF . However , a copy of the completed
report is maintained in the investigator sit e file.
An EDB report is not created when a [COMPANY_007] drug specificall y approved for use in 
breastfeeding women (eg, vitamins) is administered in accord ance with authorized use. 
However , if the infant experiences an SAE associated with such a drug, the SAE is reported 
together with the EDB .
[IP_ADDRESS]. Occupational Exposure
The investigator must report any  instance of occupational exposure to [COMPANY_007] Safet y within 
24hours of the investigator ’s awareness using the Vaccine SAE Report Form or via 
PSSA , 
regardless of whether there is an associated SAE. Since the information about the 
occupational exposure does not pertain to a participant enrolled in the study , the information 
is not recorded on a CRF; however , a copy  of the completed
report ismaintained in the 
investigator site file .
8.4.6. Cardiovascular and Death Events
Deaths and cardiovascular events will be recorded throughout the study  as detailed in
Section 8.4.1.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 618.4.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AE s 
or SAEs
Not applicable .
8.4.8. Adverse Events of Special Interest
The following events are protocol-specified AESIs:
Confirmed COVID -19 diagnosis (clinical signs/s ymptoms and positive SARS -CoV -[ADDRESS_799383]) after Visit 1 through the end of the study .
Confirmed diagnosis of my ocarditis or pericarditis occurring after vaccination. See
Section 8.10.5.
Potential menstrual cy cle disturbances. See Section 8.10.6.
GBS .
Neuritis ,including Bell’s 
palsy .
Vasculitis.
AESI sare examined as part of routine safet y data review procedures throughout the clinical 
trial and as part of signal detection processes. Should an aggregate analy sis indicate that 
these prespecified events occur more frequentl y than expected, eg, based on epi[INVESTIGATOR_227924], literature, or other data, then this will be submitted and reported in accordance with 
[COMPANY_007]’s safet y reporting re quirements. Aggregate anal yses of safet y data will be performed 
on a regular basis per internal SOPs
.
All AESI s must be reported as an AE or SAE following the procedures described in 
Section 8.4.[ADDRESS_799384] be reported using Vaccine SAE Report Form
or via 
PSSA .
[IP_ADDRESS]. Lack of Efficacy
The investigator must report signs, s ymptoms, and/or clinical sequelae resulting from lack of 
efficac y. Lack of ef ficacy or failure of expected pharmacological action is reportable to [COMPANY_007] 
Safety  only if associated with an SAE .  
8.4.9. Medical Device Deficiencies
Medical 
devices being provided for use in this study are those listed in Section 6.1.2. In order 
to fulfill regulatory  reporting obligatio
ns worldwide, the unblinded site staff is responsible 
for the detection and documentation of events meeting the definitions of device deficiency
that occur during the study with such devices.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 62The definition of a medical device deficiency can be found in Appendix 7.
Note: A
Es and/or SAEs that are associated with a medical device deficiency  will follow the 
same processes as other AEs or SAEs, as outlined in Sections 8.4.1 through 8.4.4 and
Appendix 3 of the protocol.
[IP_ADDRESS]. Time Period for Detecting Medical Device Deficiencies
Medical device deficiencies that result in an incident will be detected, documented, and 
reported during all periods of the study in which the medical device is used.
Importantly , reportable device defi ciencies are not limited to problems with the device itself 
but also include incorrect or improper use of the device and even intentional misuse, etc. 
If the unblinded site staff learns of an y device deficiency at any  time after a participant has 
been dis charged from the study , and such deficiency is considered reasonably  related to a 
medical device provided for the study , the unblinded site staff will promptly  notify  the 
sponsor .
Refer to Section 10.7.4 for instructions for documenting and reporting medical device 
deficiencies. 
[IP_ADDRESS]. Follow -Up of Medical Device Deficiencies
Follow -up applies to all participants, including those who disc ontinue study  intervention.
The unblinded site staf f areresponsible for ensuring that follow -up includes any  
supplemental investigations as indicated to elucidate the nature and/or causality  of the 
deficiency .
New or updated information will be recorded o n a follow -up form with all changes signed 
and dated b y the unblinded site staf f.
[IP_ADDRESS]. Regulatory Reporting Requirements for Device Deficiencies
The unblinded site staff will promptly  report all device deficiencies occurring with an y 
medical device provided for use in the study  in order for the sponsor to fulfill the legal 
responsibility  to notify  appropriate regulatory  authorities and other entities about certain 
safet y information relating to medical devices being used in clinical studies.
Theunblinded site s taff, or responsible person according to local requirements (eg, the head 
of the medical institution), will comply  with the applicable local regulatory requirements 
relating to the reporting of device deficiencies to the I RB/EC.
Note: There are additional reporting obligations for medical device deficiencies that are 
potentially  related to SAEs (ie, an SADE) that must fulfill the legal responsibility  to notify  
appropriate regulatory  authorities and other entities about certain safet y information relating 
tomedical devices being used in clinical studies.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 63Any device deficiency  that is associated with an SAE must be reported to the sponsor 
within 24 hours after the investigator determines that the event meets the definition of a 
device deficiency .
The sponsor shall review all device deficiencies and determine and document in writing 
whether they  could have led to an SAE. These shall be reported to the regulatory  
authorities and IRBs/ECs as required b y national regulations.
8.4.10. Vaccination Errors
Vaccination errors may  result from the administration or consumption of the study  
intervention by [CONTACT_19995] , or at the wrong time, or at the wrong dosage strength.
Vaccination errors are recorded and reported as follows:
Recorded on the 
Medication Error Page 
of the CRFRecorded on the 
Adverse Event Page 
of the CRFReported on the Vaccine 
SAE Report Form/PSSA
to [COMPANY_007] Safety Within 
24 Hours of Awareness
All (regardless of whether 
associated with an AE)Any AE or SAE associated 
with the vaccination errorOnly  if associated with an 
SAE
Vaccination errors include:
Vaccination errors involving participant exposure to the study  intervention ;
Potential vaccination errors or uses outside of what is foreseen in the protocol that do or 
do not involve the study participant ;
The administration of expi[INVESTIGATOR_214312];
The administration of an incorrect study  intervention;
The administration of an incorrect dosage;
The administration of study  intervention that has undergone temperature excursion from 
the specified storage range, unless it is determined by  [CONTACT_214348].
The administration of the prepared combined vaccine after more than 4 hours of 
storage at 25
°C. 
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 64Whether or not the vaccinat ion error is accompanied by  [CONTACT_1149], as determined by  [CONTACT_1275] , such vaccination errors occurring to a study  participant are recorded on the 
medication error page of the CRF , which is a specific version of the AE page and, if 
applicable, an y associated serious and nonserious AE(s) are recorded on the AE page of the 
CRF.
In the event of a 
vaccination dosing error , the sponsor should be notified within 24 hours .
Vaccination errors should be reported to [COMPANY_007] Safety  within 24 hours on a Vaccine SAE 
Report Form orvia 
PSSA only when associated with an SAE.
8.5.Pharmacokinetics 
Pharmacokinetic parameters are not evaluated in this study . 
8.6.Genetics
Not applicable.
8.7.Biomarkers
Biomarkers are not evaluated in this study .
8.8.Immunogenicity Assessments
Refer to Section 8.2. 
8.9.Health Economics
Health e conomics/ medical resource utilization and health e conomi csparameters are not 
evaluated in this study .
8.10. Study Procedures
8.10.1.
Visit 1 – Vaccination (Day 1)
Before enrollment and before an y stud y
-related procedures are performed, voluntary , written, 
study -specific informed consent will be obtained from the participant . Each signature [CONTACT_228020] y dated b y the signatory. The investigator or his or her designee will 
also sign the ICD. A copy  of the signed and dated I CD must be given to the participant. The 
source data must reflect that the informed consent was obtained before participation in the 
study .
It is anticipated that the procedures below will be conducted in a stepwise manner.
Assign a single participant number using the IRT sy stem.
Obtain the participant’s demograph y (including age in years, sex, race, and ethnicity ).
Obtain medical history  and any  other medical history  of clinical significance.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 65On the day  of and prior to study  intervention administration, perform a clinical 
assessment. If the clinical assessment indicates that a ph ysical ex amination is necessary  
to comprehensivel y evaluate the participant, perform a ph ysical examination and record 
any findings in the source documents and, if clinically  significant, record findings on the 
medical history  CRF.
Measure the participant’s height and weight.
On the day  of and prior to study  intervention administration, measure the participant’s 
oral temperature and seated blood pressure. 
Record nonstud y vaccinations and prior receipt of any licensed or investigational 
COVID -19 or influenza vaccine as described in Section 6.9.
On the day  of and prior to study  intervention administration, perform a urine pregnancy  
test on WOCBP a s described in Section 8.3.6.
If applicable, discuss contraceptive use as described in Section 10.4.4.
On the day  of and prior to study  intervention administration, ensure and document that all 
of the inclusion criteria and none of the exclusion criteria are m et.
On the day  of and prior to study  intervention administration, ensure that the participant 
meets none of the temporary  delay  criteria as described in 
Section 5.5.
On the day  of and prior to study  intervention administration, obtain the participant’s 
randomization number and study  intervention allocation using the IRT system.
On the day  of and prior to study  intervention administration, c ollect a blood sample 
(approximately  20 mL), before administration of study  intervention, for immunogenicit y 
assessment.
Site staff member(s) will dispense/administer 2 injections
(1in each arm) into the deltoid 
muscle of the prescribed armbased onthestudy  intervention allocation asdetailed in
Table 3.Please refer to the I PM for further instruction on this process.
S
ite staff must observe the participant for at least [ADDRESS_799385] an y acute reactions (including time of 
onset) in the participant’s source documents, on the CRF, and on an SAE form as 
applicable.
Explain the e -diary  technologies available for this study  (see Section 8.3.4), and assist the 
participant in downloading the stud y application onto the participant’s own device or 
issue a provisioned device if required.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 66Provide instructions on reactogenicity  e diary  completion and ask the participant to 
complete the reactogenicity  e-diary  from Day  1 through Day  7 or longer until any  
symptoms that are ongoing are resolved, with Day  1 being the day  of vaccination.
Issue a measuring device to measure local reactions at the injection site and a 
thermometer for recording dail y temperatures; provide instructions on their use.
Ask the participant to contact [CONTACT_214350] y if the 
participant experiences any  of the following from Day  1 through Day 7 after 
vaccination (where Day  1 is the day  of vaccination) to determine if an unscheduled 
reactogenicity visit is required:
Fever ≥39.0°C ( ≥102.1°F).
Redness or swelling at the injection site measuring greater than 10 cm 
(20 measuring device units).
Severe pain at the injection site.
Any severe s ystemic event.
Record AEs as described in Section 10.3.
Ask the participant to contact [CONTACT_214351] a medicall y attended event 
(eg, doctor’s visit, emergency  room visit) or hospi[INVESTIGATOR_149323].
Ask the participant to contact [CONTACT_603732], shortness of breath, or palpi[INVESTIGATOR_814] (see Section 8.10.5).
Schedule an appointment for the participant to return for the next study  visit.
Remind the participant to bring the e -diary  to the next visit.
Complete the source documents.
The investigator or an authorized designee completes the CRFs and a
dispenser/administrator updates the study  intervention accountability  records.
The investigator or appropriately  qualified designee reviews the reactogenicity
e
-diary  data online and records the assessment in the CRF following vaccination to 
evaluate participant compliance and as part of the ongoing safet y review. Daily review is 
optimal during the active diary  period.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 678.10.2. Visit 2 – 4-Week Follow-Up Visit (After Vaccination) – 28 to 35 Days After 
Visit 1
Record AEs as described in Section 8.4.
Record nonstud y vaccinations as described in Section 6.9.
If applicable, discuss contraceptive use as described in Section 10.4.4.
Collect a blood sample of approximately  20 mL for immunogenicit y testing.
Review the participant’s reactogenicity  e-diary  data and record assessment in the CRF. 
Assess compliance, record any medicall y attended events (including hospi[INVESTIGATOR_602]), 
and collect stop dates for any  symptoms/medications ongoing on the last day  of the 
e
-diary  collection period in the CRF. For s ymptoms still ongoing, continue to follow up 
until resolution, and document and record stop dates in the CRF.
Record reactogenicity  medication used as described in Section 8.3.4.
Ask the participant to contact [CONTACT_214351] a medicall y attended event 
(eg, doctor’s visit, emergency  room visit) or hospi[INVESTIGATOR_149323].
Collect the participant’s e
-diary  or assist the participant with removing the study  
application from his or her own personal device.
Complete the source documents.
The investigator or an authorized designee completes the CRFs.
Record any AEs that occur within the 48 hours after the blood draw as described in
Section 8.4.
8.10.3.
Visit 3 – 6- Month Follow - Up Visit (After Vaccination) – 175 to 189 Days After 
Visit 1
Record SAEs and AESIs as described in Section 8.4.
Record nonstudy  vaccinations as described in Section 6.9.
Collect a blood sample of approximately  20 mL for immunogenicit y testing.
Compl ete the source documents.
The investigator or an authorized designee completes the CRFs.
Record an y AEs that occur within the 48 hours after the blood draw as described in
Section 8.4.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 688.10.4. Unscheduled Visit for a Grade 3 or Suspected Grade 4 Reaction
If a Grade 3 local reaction ( Section [IP_ADDRESS] ), systemic event ( Section [IP_ADDRESS] ), or fever 
(Section [IP_ADDRESS]) is reported in the reactogenicit y e-diary , a telephone contact [CONTACT_214354] a sit e visit is clinically  indicated. If a 
suspected Grade 4 local reaction ( Section [IP_ADDRESS]), sy stemic event ( Section [IP_ADDRESS]), or fever 
(Section [IP_ADDRESS]) is reported in the reactogenicit y e-diary , a telephone contact [CONTACT_603733] [ADDRESS_799386] be scheduled as soon as possi ble to assess the participant unless any  of the 
following is true:
The participant is unable to attend the unscheduled visit.
The local reaction/s ystemic event is no longer present at the time of the telephone 
contact.
The participant recorded an incorrect value in the reactogenicity  e-diary  (confirmation of 
a reactogenicit y e-diary  data entry  error).
The PI  [INVESTIGATOR_214313].
This telephone contact [CONTACT_214356]’s source documentation and the 
CRF.
If the participant is unable to attend the unscheduled visit, or the PI  [INVESTIGATOR_227942], an y ongoing local reactions/sy stemic events must be followed
daily  until resolution .
During the unscheduled visit, the reactions shoul d be assessed b
y the investigator or a 
medically  qualified member of the study  staff, such as a study  physician or a study  nurse, as 
applicable to the investigator’s local practice, who will:
Measure oral temperature (°F/°C).
Measure minimum and maximum diameters of redness (if present).
Measure minimum and maximum diameters of swelling (if present).
Assess injection site pain (if present) in accordance with the grades provided in
Section [IP_ADDRESS] .
Assess sy stemic events (if present) in accordance with the grades provided in
Section [IP_ADDRESS] .
Assess for other findings associated with the reaction and record these on the CRF if 
appropriate.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 69The investigator or an authorized designee will complete the unscheduled visit assessment 
page of the CRF.
8.10.5. Additional Proce dures for Monitoring of Potential Myocarditis or Pericarditis
Any study  participant who reports the following within [ADDRESS_799387], for possible myocarditis or 
pericarditi s: 
Acute chest pain, 
Shortness of breath, 
Palpi[INVESTIGATOR_814], or 
Any other s ymptom(s) that might be indicative of my ocarditis or pericarditis.
In addition to a clinical evaluation, the following should be performed:
ECG and
Measurement of the troponin level.
If my ocarditis or pericarditis is suspected based upon the initial evaluation, the following 
should also be performed:
Cardiac echocardiogram and/or
Cardiac magnetic resonance study .
Details of the s ymptoms reported, and results of the investigations perf ormed, will be 
recorded in the CRF. Any diagnosis made (myocarditis, pericarditis, or other) should be 
recorded as an S AE. Refer also to Section 8.4.8.
8.10.6. Additional Procedures for Monitoring of Potential Menstrual Cycle 
Disturbances
Any female study  participant who reports any  symptoms that may  indicate a disturbance of 
their normal menstrual cycle (including, but not exclusively , heav y menstrual bleeding, 
amenorrhea, irregular periods) following receipt of study  intervention until [ADDRESS_799388] vaccination should be specifically  evaluated by  [CONTACT_093]. Details of the sy mptoms, 
menstrual history , and results of any  inve stigations performed will be recorded in the CRF.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 709.STATISTICAL CONSIDERATIONS
Methodology for summary  and statistical anal yses of the data collected in this study  is 
described here and further detailed in the SAP, which will be maintained by [CONTACT_456]. The 
SAP may  modify  what is outlined in the protocol where appropriate; however, any  major 
modifications of the primary  endpoint definitions or their anal yses will also be ref lected in a 
protocol amendment.
9.1.Statistical Hypotheses
There is no formal hypothesis testing. All statistical anal yses will be descriptive .
9.1.1. Estimands
The estimands corresponding to the primary  objectives are described in the table in 
Section 3.
The safet y primary objective evaluations are based on the safet y population. I n general, 
completely  missing reactogenicity  data (ie, all 7 day s of collection were missing) will not be 
imputed. For partiall y missed reactogenicit y data (eg, 1 -6 day s of reactogenicity  data are 
available), it is assumed that no reactions or events were experienced on the missing day s. 
Missing AE start dates will be imputed according to [COMPANY_007] safety  rules. No other missing 
information w ill be imputed in the safet y anal ysis.
The estimands to evaluate the immunogenicity  objective are based on the evaluable 
immunogenicit y population ( Section 9.2). These estimands estimate the vaccine effect in the 
hypothetical setting where participants follow the study  schedules and protocol requirements 
as directed. Missing antibody  results will no
t be imputed. I mmunogenicit y results that are 
below the LLOQ will be set to 0.5 × LLOQ in the anal ysis. This may  be adjusted once 
additional data on the assay  characteristics become available.
9.1.2. Multiplicity Adjustment
No multiplicity  adjustment is needed fo r the stud y as there is no statistical hy pothesis.
9.2.Analysis Sets
For purposes of analy sis, the following anal ysis sets are defined:
Participant Analysis Set Description
Screened All participants who have a signed ICD.
Randomized All participants who are assigned a randomization number in 
the IRT s ystem.
Safety  All participants who receive at least 1 dose of the study  
intervention.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 71Participant Analysis Set Description
Evaluable immunogenicity All eligible assigned participants who receive the study  
intervention to which they  are assigned, have at least [ADDRESS_799389] 1 valid and determinate immunogenicit y result after 
vaccination.
9.3. Statistical Analyses
The SAP will be developed and finalized before any anal yses are pe rformed and will 
describe the anal yses and procedures for accounting for missing, unused, and spurious data.
This section is a summary of the planned statistical analy ses of the primary  and exploratory
endpoints.
9.3.1. General C onsiderations
Other than IRC review of earl y Phase 1 safet y data before initiation of Phase 2 enrollment, 
data from Phase 1 and Phase 2 participants will be combined for the safet y and 
immunogenicit y analyses.
CIs for all endpoints in the statistical anal ysis will be presented as 2-sided at the 95% level 
unless specified otherwise.
The safe ty anal yses are based on the safet y population. Participants will be summarized by  
[CONTACT_227990] y received.
For all the immunogenicity  endpoints, the analy sis will be based on the evaluable 
immunogenicit y population. An additional anal ysis may  be performed based on the 
all-available immunogenicity  population if there is a large enough difference in sample size 
between the all -available immunogenicit y population and the evaluable immunogenicit y 
population. Pa rticipants will be summarized according to the vaccine group to which they  
were randomized.
[IP_ADDRESS]. Analysis for Binary Data
Descriptive statistics for categorical variables (eg, proportions) are the percentage (%), the 
numerator (n) and the denominator (N) used i n the percentage calculation, and the 95% CIs, 
where applicable.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 72The exact 95% CI for binary  endpoints for each group will be computed using the 
Fdistribution (Clopper -Pearson).40The 95% CI for the between -group difference for binary  
endpoints will be calculated using the Miettinen and Nurminen method.
[IP_ADDRESS]. Analysis for Continuous Data
Unless otherwise stated, descriptive statistics for continuous variables are n, mean, median, 
standar d deviation, minimum, and maximum.
[IP_ADDRESS].1. Geometric Means
The geometric means will be calculated as the mean of the assay  results after making the 
logarithm transformation and then exponentiating the mean to express results on the original 
scale. Two- sided 95% CI s will be obtained by  [CONTACT_603734], 
calculating the 95% CI with reference to the Student t distribution, and then exponentiating 
the confidence limits.
[IP_ADDRESS].2. Geometric Mean Ratios
Model -Based GMR :
The GMR and associated 95% CI  will be calculated by  [CONTACT_603735] a linear regression model that includes terms for baseline assay results
(log scale), age, and comparison group.
Unadjusted GMR :
The GMR will be calculated as the mean of the difference of logarithmically transformed 
assay  results and exponentiating the mean. Two- sided CI s will be obtained by  [CONTACT_603736] t distribution for the mean difference of the logarithmically  transformed 
assay  results and exponentiating the confidence limits.
[IP_ADDRESS].3.
Geometric Mean Fold Rises
GMFRs are defined as ratios of the results after vaccination to the results before vaccination. 
GMFRs are limited to participants with nonmissing values at both time points. GMFRs will 
be calculated as the mean of the difference of logarithmically  transformed assay  results (later 
time point minus earlier time point) and exponentiating the mean. The associated 2 -sided 
95% CIs will be obtained by  [CONTACT_227992] t distribution for the mean 
difference on the logarithm scale and exponentiating the confidence limits.
[IP_ADDRESS].4. Reverse Cumulative Distribution Curves
Empi[INVESTIGATOR_214315] a 
specified assay  value versus the indicated assay  value, for all observed assay  values. Data 
points will be joined by  a step function with data points on the left side of the step.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 739.3.2. Primary Endpoint(s) /Estimand(s) Analysis
Endpoint Statistical Analysis Methods
Safety Descriptive statistics will be provided for each reactogenicity  endpoint
for each vaccine group . Local reactions and s ystemic events from Day  1 
through Day  7 after vaccination (where Day  1 is the day  of vaccination) 
will be presented b y severity  and cumulatively  across severity  levels. 
Descriptive summary  statistics will include counts and percentag es of 
participants with the indicated endpoint and the associated 
Clopper -Pearson 95% CIs.
AEs and SAEs will be categorized according to MedDRA terms. 
Counts, percentages, and associated Clopper -Pearson 95% CI s of AEs 
from vaccination through 4 weeks and SAEs from vaccination through 
6 months after vaccination will be provided for each vaccine group .
Immunogenicit yGMTs and 2 -sided 95% CI s of SARS -CoV -2 Omicron
(XBB.1.5 )–neutralizing titers and strain -specific HAI titers (for the 
seasonal strains recommended by  [CONTACT_120055]) before vaccination and at 
4weeks after vaccination will be provided for each vaccine group . 
Statistical methods are described in Section [IP_ADDRESS].1 .
GMFRs of SARS -CoV -
2 Omicron ( XBB.1.5 ) –neutralizing titers and 
strain- specific HAI titers (for the seasonal strains recommended b y 
WHO) from before vaccination to 4 weeks after study  vaccination , 
along with the associated 2- sided 95% CIs, will be provided for each 
vaccine group . Statistical methods are described in Section [IP_ADDRESS].3.
The percentages of participants with seroresponse to SARS -CoV -
2 
Omicron ( XBB.1.5 ) at 4 weeks after vaccination, the percentage sof 
participants with HAI seroconver sionat 4 weeks after vaccination, 
and percentages of participants with HAI  titers ≥ 1:40 before 
vaccination and at 
4 weeks after vaccination and the associated 
Clopper -Pearson 95% CIs will be provided for each vaccine group .
9.3.3. Secondary Endpoint(s) /Estimand(s) Analysis
Not applicable .
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 749.3.4. Tertiary/Exploratory Endpoint(s) Analysis
Immunogenicit yGMTs and 2 -sided 95% CI s of SARS -CoV -2 Omicron 
(XBB.1.5) –neutralizing titers and strain -specific HAI titers (for the 
seasonal strains recommended by  [CONTACT_120055]) before vaccination and at 
6 months after vac cination will be provided for each vaccine group. 
Statistical methods are described in Section [IP_ADDRESS].1 .
GMFRs of SARS -CoV -2 Omic ron (XBB.1.5) –neutralizing titers 
and strain
-specific HAI titers (for the seasonal strains 
recommended b y WHO) from before vaccination to 6 months after 
study  vaccination , along with the associated 2- sided 95% CIs, will 
be provided for each vaccine group. Statistical methods are 
described in Section [IP_ADDRESS].3 .
The percentages of participants with seroresponse to SARS -CoV -2 
Omicron (XBB.1.5) at 6 months after vaccination, the percentages 
of participants with HAI seroconversion at 6 months after 
vaccination, and percentages of participants with HAI titers ≥ 1:40 
before vaccination and at 6 months after vaccination and the 
associated Clopper -Pearson 95% CI s will be provided for each 
vaccine group.
Immune response 
to emerging 
variantsFor SARS -CoV -2-ne utralizing titers and/or HAI titers for emerging 
variants (under monitoring, of interest, and/or of concern), GMTs, 
GMFRs, percentages of participants with seroresponse , and 
percentages of participants with seroconversion or HAI titers ≥ 1:40
at the specifi c time point, along with the associated 95% CI s, will 
be summarized in the same way  as for the immunogenicity  primary  
endpoints described above. This anal ysis may  be conducted in a 
selected subset of participants.
Descriptive 
comparison of 
immune responseGMRs and the differences in percentages of participants with 
seroresponse to SARS -CoV -2 Omicron (XBB.1.5) and with HAI 
seroconversion between certain groups of interest will be calculated 
along with the associated 2- sided 95% CIs.
HAI titers b y virus 
microneutralization 
assayFor HA I titers measured by  [CONTACT_603737] s, 
GMTs, GMFRs, and percentages of participants with 
seroconversion or HAI titers ≥ 1:40 at the specific time point, along 
with the associated 95% CI s, will be summarized in
the same way  
as for the immunogenicity  primary  endpoints described above. This 
analysis may  be conducted in a selected subset of participants.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 759.4.Interim Analyses
No interim anal ysis will be conducted for this study .As this is a sponsor –open -label study ,
[COMPANY_007] may  conduct unblinded reviews of the data during the course of the study  for the 
purpose of safet y assessment and/or supporting clinical development. Statistical analy ses will 
be carried out when the final data for specified objectives are availabl e while the study  is 
ongoing. The timing of these planned anal ysis and reporting events is described in 
Section 9.4.1 .
9.4.1. Analysis Timing
Statistical analy ses will be carried out when the following data are available:
Safety  and immunogenicity  data through 4 weeks after vaccination.
Safety  and immunogenicity  data through [ADDRESS_799390] 
development, and/or for program
-level decisions. Certain anal yses may  be combined as 
1regulatory  submission report if the data become available around the same time.
9.5.Sample Size Determination
The sample size is not based on an yformal hy pothesis test. All statistical analy ses will be 
descriptive.
For safet y outcomes , Table 7shows the probability of observing at least 1 AE fo r a given 
true event rate of a particular AE. For example, if the true AE rate is 1%, with approximately  
160participants in a vaccine group, there is 80% probability  of observing at least [ADDRESS_799391] 1 AE, by [CONTACT_603738]=20 N=80 N=160 N=640
0.1% 0.02 0.08 0.15 0.47
0.5% 0.10 0.33 0.55 0.96
1% 0.18 0.55 0.80 0.99
2% 0.33 0.80 0.96 0.99
3% 0.46 0.91 0.99 0.99
4% 0.56 0.96 0.99 0.99
5% 0.64 0.98 0.99 0.99
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 7610. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines , including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines ;
Applicable ICH GCP guidelines;
Applicable laws and regulations , including applicable privacy  laws .
The protocol, protocol amendments, I CD, SRSD(s) , and other relevant documents 
(eg, advertisements) must be 
reviewed and approved by  [CONTACT_456] ,submitted to an I RB/EC 
by [CONTACT_093], and reviewed and approved by  [CONTACT_1201]/EC before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
Protocols and an y sub stantial amendments to the protocol will require health authority  
approval prior to initiation except for changes necessary to eliminate an immediate hazard to 
study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or more 
frequentl y in accordance with the requirements, policies, and procedures established by 
[CONTACT_1201]/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by [CONTACT_1744]/EC 
procedures ;
Providing oversight of the conduct of the stud y at the site and adherence to requirements 
of 21 CFR, I CH GCP guidelines, the I RB/EC, European regulation 536/[ADDRESS_799392] 2017/745 for clinical device research, and all ot her applicable 
local regulations .
[IP_ADDRESS]. Reporting of Safety Issues and Serious Brea ches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if th e investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the study  
intervention , [COMPANY_007] should be informed immediately . 
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 77In addition, the investigator will inform [COMPANY_007] immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study participants against an y immediate hazard, and 
of an y serious breaches of this protocol or of the ICH GCP  guidelines that the investigator 
becomes aware of.
10.1.2.
Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certificatio n or disclosure statements to the appropriate regulatory  authorities. Investigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent Process
The investigator or the investigator’s representative will explain the nature of the study , 
including the risks and benefits, to the participant and answer all questions regarding the 
study . The participant should be given suf ficient time and opportunity  to as k questions and to 
decide whether or not to participate in the trial.
Participants must be informed that their participation is voluntary . Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, privacy  and data protection requirements, where 
applicable, and the IRB/EC or study  center .
The investigator must ensure that each participant is fully  informed about the nature and 
objectives of the study , the sharing of data related to the study ,and possible risks associated 
with participation, including the risks associated with the processing of the participant ’s 
personal data. 
The participant must be informed that their personal study -related data will be used by  [CONTACT_20004] . The level of disclosure must also be 
explained to the participant.
The participant must be informed that their medical records may  be examined by  [CONTACT_160439] , by 
[CONTACT_6667]/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure that each study  participant is fully  informed about their
right to access and correct their personal data and to withdraw consent for the processing of 
their personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the date on which the written consent was 
obtain ed. The authorized person obtaining the informed consent must also sign the IC D
.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 78Participants must be reconsented to the most current version of the IRB/EC -approved ICD(s) 
during their participation in the study as required per local regul ations.
A copy ofthe IC D(s) must be provided to the participant.
Participants who are rescreened are required to sign a new IC D.
[IP_ADDRESS]. Electronic Consent
Participants may  be able to experience the informed consent process by  [CONTACT_10075] 
(eConsent). The eConsent process includes an electronic presentation of the informed 
consent document (eICD), clinical trial educational components (as applicable), and
electronic signatures (if allowed by  [CONTACT_427]). The use of eConsent does not replace 
or alter the ICD content or informed consent process as described above. The eConsent 
process complies with applicable regulations and sponsor policies to ensure reliability  and 
data privacy . 
10.1.4. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data wi ll be stored at the study  site in encry pted electronic and/or paper
form and will be password protected or secured in a locked room to ensure that only  
authorized study  staff have access. The stud y site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster . In the event of a potential personal data breach, the study site will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, pro viding breach 
notifications as required by  [CONTACT_2371].
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. Any 
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  [CONTACT_20007], participant- specific code. The study site will 
maintain a confidential list of participant s who participated in the study , linking each 
participant ’s numerical code to their actual identity and medical record ID. In case of data 
transfer , the sponsor will protect the confidentiality  of participant s’ personal data consistent 
with the c linical study agreement and applicable privacy  laws.
Information technology  systems used to collect, process, and store study -related data are 
secured b y technical and organizational securit y measures designed to prote ct such data 
against accidental or unlawful loss, alteration, or unauthorized disclosure or access.
The sponsor maintains SOPs on how to respond in the event of unauthorized access, use, or 
disclosure of sponsor information or sy stems.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 7910.1.5. Committees Structure
[IP_ADDRESS]. Data Monitoring Committee 
This study  will use an IRC. The I RC is independent of the study team and includes only  
internal members. The IRC charter describes the role of the IRC in more detail.
The I RC will be responsible for ongoing monitoring of the saf ety of participants in the study  
according to the charter . The recommendations made b y the IRC will be forwarded to the 
appropriate authorized [COMPANY_007] personnel for review and final decision. [COMPANY_007] will 
communicate such decisions, which may  include summari es of aggregate analy ses of safet y 
data, to regulatory  authorities and investigators, as appropriate. 
10.1.6. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www .clinicaltrials.gov (ClinicalT rials.gov), the EudraCT /CTI S, and/or 
www .pfizer .com, and other public registries and websites in accordance with applicable local 
laws/regulations. In addition, [COMPANY_007] reports study  results outside of the requirements of l ocal 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.
www.clinicaltrials.gov
[COMPANY_007] posts clinical trial results on www .clinicaltrials.gov for [COMPANY_007] -sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or ef ficacy  of a product, 
regardless of the geographical location in which the study  is conducted. These r esults are 
submitted for posting in accordance with the format a nd timelines set forth by  [CONTACT_20008].
EudraCT /CTI S
[COMPANY_007] posts clinical trial r esults on EudraCT /CTI Sfor [COMPANY_007] -sponsored interventional studies 
in accordance with the format and timelines set forth by  [CONTACT_20009].
www.pfizer.com
[COMPANY_007] posts CSR s ynopses and plain- language study  results summaries on www .pfizer .com 
for [COMPANY_007] -sponsored interventional studies at the same time the corresponding study  results 
areposted to www.clinicaltrials.gov. CSR sy nopses will have personally  identif iable 
information ano nymized.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 80Documents within marketing applications
[COMPANY_007] complies with applicable local laws/regulations to publish clinical documents included 
in marketing applications. Clinical documents include summary  documents and CSRs 
including the protocol and proto col amendments, sample CRFs, and SAPs. Clinical 
documents will have personally  identifiable information anony mized.
Data sharing
[COMPANY_007] provides researchers secure access to participant -level data or full CSRs for the 
purposes of “ bona -fide scientific research” that contribute sto the scientific understanding of 
the disease, target, or compound class. [COMPANY_007] will make data from these trials available 
18months after study  completion. Participant -level data will be anon ymized in accordance 
with applicabl e privacy  laws and regulations. CSRs will have personall y identifiable 
information anon ymized.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analy ses.Research teams must include a biostat istician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.7. Data Quality Assurance
All participant data relating to the stud y will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  [CONTACT_20010] .
Guidance on completion of CRFs will be provided in the CRF Completion Requirements 
document .
The investigator must ensure that the CRFs are securel y stored at the study site in encry pted 
electronic and/or paper form and are password protected or secured in a locked room to 
prevent access b y unauthorized third parties.
QTL s are predefined parameters that are monitored during the study . Important deviations 
from the QTLs and any remedial actions taken will be summarized in the CSR.
The investigator must permit study -related monitoring, audits, IRB/EC review , and 
regulatory  agency  inspections and provide direct access to source records and documents.
This verification may  also occur after study  completion. I t is important that the 
investigator(s) and their relevant personnel are available during the monitoring visits and 
possible audits or inspections and that suf ficient time is devoted to the process.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 81Monitoring details describing strategy , including definition of study -critical data items and 
processes (eg, risk- based initiatives in operations and quality  such as risk management and 
mitigation strategies and analytical risk-based monitoring), methods, responsibilities ,and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual , or on- site monitoring) , are provided in the data management plan and 
monitoring plan maintained and utilized by  [CONTACT_36613].
The sponsor or designee is responsible for the data management of this study ,including 
quality  checking of the data.
Records and documents, including signed IC Ds, pertaining to the conduct of this study  must 
be retained b y the investigator for 15years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the sponsor . No records may  be 
transferred to anothe r location or part y without written notification to the sponsor .The 
investigator must ensure that the records continue to be stored securel y for aslong as they  are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_78245] y deleted from all systems.
The investigator(s) will notify thesponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study . Furthermore, the investigator will coopera te 
with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly  resolve any  discrepa ncies that are identified 
between the stud y data and the participant ’s medical records. The investigator will promptly  
provide copi[INVESTIGATOR_19946]. Before response 
submission to the regulatory  authorities, the inve stigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.
10.1.8. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source document s are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained . The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also, current medical records must be available.
Definition of what constitutes asource document and its origin can be found in the Source 
Document Locator , which is maintained by [CONTACT_456] .
Description of the use of the computerized sy stem is documented in the data management 
plan, which is maintained by  [CONTACT_456] .
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 82The investigator must maintain accurate documentation (source record) that supports the 
information entered in the CRF .
The sponsor or designee will perform monitoring to confirm that data entered into the CRF 
by [CONTACT_1191], complete, and verifiable from source documents; 
that the safet y and rights of participants are being protected; and that the study is being 
conducted in accordance with t he currentl y approved protocol and an y other study  
agreements, I CH GCP guidelines, and all applicable regulatory  requirements.
10.1.9. Use of Medical Records
There may  be instances when copi[INVESTIGATOR_296040] , where ethically  and scientifically  justified and permitted by  [CONTACT_427], 
to ensure participant safety .
Due to the potential for a participant to be re -identified from their medical records, the 
following actions must be taken when medical records are sent to the sponsor or sponsor 
designee:
The investigator or site staff must redact personal information from the medical record. 
The personal information includes, but is not limited to, the following: participant names 
or initials, participant dates (eg, birth date, date of hospi[INVESTIGATOR_063]/discharge, date of 
death), participant identification numbers (eg, Social Security  number, health insurance 
number, medical record number, hospi[INVESTIGATOR_307]/institution identifier), p articipant location 
information (eg, stre et address, cit y, country, postal code, I P address), participant contact 
[CONTACT_3031] (eg, telephone/fax number, email address) .
Each medical record must be transmitted to the sponsor or sponsor designee using 
systems with technical and organizational secur ity measures to ensure the protection of 
personal data (eg, Florence is the preferred s ystem if available). 
There may  be unplanned situations where the sponsor may  request medical records 
(eg, sharing medical records so that the sponsor can provide study -related advice to the 
investigator). The medical records should be submitted according to the procedure 
described above. 
10.1.10. Study and Site Start and Closure
The study  start date is the date of the first participant’ s first visit.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor , including (but not limited to) 
regulatory  authorit y decision, change in opi[INVESTIGATOR_2511] I RB/EC, or change in benefit -risk 
assessment .Study  sites will be closed upon study completion. A study  site is considered 
closed when all required documents and study  supplies have been collected and a study -site 
closure visit has been performed.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 83The investigator may  initiate study -site clos ure at any  time upon notification to thesponsor 
or designee/ CRO if requested to do so by  [CONTACT_51025] I RB/EC or if such termination is 
required to protect the health of study  participants .
Reasons for the earl y closure of a stud y site b y the sponsor ma y include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the I RB/EC 
or local health authorities, the sponsor’s procedures, or the ICH GCP guidelines;
Inadequate recruitment of participants by  [CONTACT_3170] ;
Discontinuation of further study  intervention development .
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the E Cs/IRBs, the regulatory  authorities, and any  CRO (s) used in the study  of 
the reason for termination or suspension, as specified by  [CONTACT_20013]. The investigator shall promptly  inform the participant and should assure 
appropriate 
participant therapy  and/or follow -up.
Study  term ination is also provided for in the clinical study  agreement. If there is any  conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.11. Publication Policy
For multicenter trials, the primary  publication will be a joint publication developed b y the 
investigator and [COMPANY_007] reporting the primary  endpoint(s) of the study  covering all study  sites. 
The investigator agrees to refer to the primary  publication in any  subsequent publications. 
[COMPANY_007] will not provide any fina ncial compensation for the investigator’s participation in the 
preparation of the primary congress abstract, poster, presentation, or primary manuscript for 
the study .
Investigators are free to publish individual center results that they  deem to be clinica lly 
meaningful after publication of the overall results of the study  or [ADDRESS_799393] to the other 
requirements described in this section.
The investigator will pro vide [COMPANY_007] an opportunity to review any proposed publication or 
any other t ype of disclosure of the stud y results (collectively, “p ublication”) before it is 
submitted or otherwise disclosed and will submit all publications to [COMPANY_007] [ADDRESS_799394], remove an y previousl y undisclosed 
confidential information before disclosure, except for an y stud y-intervention or [COMPANY_007] -related 
information necessary  for the appropriate scientific presentation or understanding of the 
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 84study  results. For joint publications, should there be disagreement regarding interpretation 
and/or presentation of specific anal ysis results, resolution of, and responsibility  for, such 
disagreements will be the collective resp onsibility  of all authors of the publication.
For all publications relating to the stud y, the investigator and [COMPANY_007] will comply with 
recognized ethical standards concerning publications and authorship, including those 
established by  [CONTACT_4717]. The investigator will 
disclose an y relationship with [COMPANY_007] and any relevant potential conflicts of interest, including 
any financial or personal relationship with [COMPANY_007], in any  publications. All authors will have 
access to the relevant statistical tables, figures, and reports (in their original format) required 
to develop the publication .
10.1.12. Sponsor’s 
Medically Qualified Individual 
The contact [CONTACT_1133] ’s MQI for the study  is documented in the study  
contact [CONTACT_185623] y documentation/study  portal or other electronic 
system .
To facilitate access to their investigator and the sponsor ’s MQI for study -related medical 
questions or problems from nonstudy  healthcare professionals , participants are provided with 
an ECC at the time of informed consent. The ECC contains, at a minimum, (a) protocol and 
study  intervention identifiers, (b) participant’ s study  identification number , (c) site 
emergenc y phone number active 24 hours/day , 7 day s per week, and (d) [COMPANY_007] C all C enter 
number .
The ECC is intended to augment, not replace, the established communication pathway s 
between the participant and their investigator andsite staff, and between the inve stigator and 
sponsor study  team. The ECC is only to be used by  [CONTACT_185624] y, as a means of reaching the investigator or site staff related to the care of a 
participant. The [COMPANY_007] Call Center number is to be used when the investigator and site staff 
are unavailable . The [COMPANY_007] Call Center number is not for use by  [CONTACT_185625] y; if a 
participant calls that number directly , they will be directed back to the investigator site.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 8510.2. Appendix 2: Clinical Laboratory Tests
If appropriate, a pregnancy  test will be performed at times defined in the SoA.
Pregnancy  test (β -hCG): Local urine testing will be standard for the protocol unless 
serum testing is required by  [CONTACT_18039]/EC for participants who are WOCBP.
Unscheduled clinical laboratory  measurements may  be obtained at any  time during the study  
to assess an y perceived safet y issues. The investigator must review the laboratory report, 
document this review, and record an y clinicall y relevant changes occurring during the study  
in the AE section of the CRF.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 8610.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study  participant, 
temporally associated with the use of study  intervention, whether or not considered 
related to the stud y intervention.
Note: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding ), symptom, or disease (new or exacerbated) temporally  
associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) or 
other safet y assessments (eg, ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator .Any abnormal test results that meet 
any of the conditions below must be recorded as an AE:
Is associated with accompany ing s ymptoms
.
Requires additional diagnostic testing or medical/surgical intervention .
Leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the stu dy, significant additional concomitant 
drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition, including an increase in 
either frequency  and/or intensity  of the condition.
New condition detected or diagnosed after study  intervention administration, even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of eit her study  
intervention or a concomitant medication. Overdose per se will not be reported as an 
AEor SAE unless it is an intentional overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of sequelae.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 87Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments that are associated with the underl ying disease, unless judged by  [CONTACT_541463]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition.
Medical or surgical procedure (eg, endoscop y, app endectom y): the condition that leads 
to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of preexisting disease(s) or conditio n(s) present or 
detected at the start of the study  that do not worsen.
10.3.2. Definition of an SAE
AnSAE is defined as any untoward medical occurrence that, at any dose, meets one 
or more of the criteria listed below:
a.Results in death
b.Is life -threatening
The term “life-threatening ”in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event that
hypothetically  might have caused death if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_12994] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_227926] A Es.If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the 
AE should be considered serious.
Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen 
from baseline is not considered an AE.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 88d.Results in per sistent or significant disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance ,such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle), thatmay interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Isa suspected transmission via a [COMPANY_007] product of an infectious agent, pathogenic 
or nonpathogenic  
The event may  be suspected from clinical s ymptoms or laboratory  findings indicating 
an infection in a participant exposed to a [COMPANY_007] product. The terms “suspected 
transmission” and “transmission ” are considered sy nony mous. These cases are 
considered unexpected and handled as serious expedited cases b y pharmacovigilance 
personnel. Such cases are also considered for reporting as product defects, if 
appropriat e.
g.Other situations:
Medical or scientific judgment should be exercised by [CONTACT_78278], such as significant
medical events that may jeopardize the participant or may  require medical or 
surgical intervention to prevent one of the other outcomes listed in the above 
definition. These events should usually  be considered serious.
Examples of such events include inva sive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug 
dependency  or drug abuse.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 8910.3.3. Recording/Reporting and Foll ow-U p of A Esand/or SAE sDuring the Active 
Colle ction Period 
AE and SAE Recording /Reporting
The table below summarizes the requirements for recording AEs on the CRF and for 
reporting SAE susing the Vaccine SAE Report Form orvia PSSA to [COMPANY_007] Safety
throughout the active collection period . These requirements are delineated for 3 ty pes of 
events: (1) SAEs; (2) nonserious AEs; and (3) exposure to the study  intervention under 
study  during pregnancy  or breastfeeding, and occupational exposure. 
It should be noted that the Vaccine SAE Report Form/PSSA for reporting of SAE 
information is not the same as the AE page of the CRF. When the same data are collected, 
the forms must be completed in a consistent manner. A Esshould be recorded using 
concise medical terminology  and the same AE term should be used on both the CRF and 
the Vaccine SAE Report Form/PSSA for reporting of SAE information.
Safety Event Recorded on the CRF Reported on the Vaccine 
SAE Report Form/PSSA
to [COMPANY_007] Safety Within 
24Hours of Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeeding All AEs or SAEs associated 
with EDP or EDB
Note: I nstances of EDP or 
EDB not associated with an 
AE or SAE are not captured 
inthe CRFAll instances of EDP are 
reported (whether or not 
there is an associated 
SAE)*
All instances of EDB are 
reported (whether or not 
there is an associated 
SAE)**
Environmental or 
occupational exposure to 
the product under stud y to 
a nonparticipant (not 
involving EDP or EDB)None. Exposure to a study 
nonparticipant is not 
collected on the CRFThe exposure (whether or 
not there is an associated 
AE or SAE) must be 
reported***
*EDP (with or without an associated SAE) is reported to [COMPANY_007] Safety using the Vaccine SAE Report 
Form and EDP Supplemental Form or via PSSA . 
**EDB is reported to [COMPANY_007] Safety using the Vaccine SAE Report Form orvia PSSA ,which would 
also include details of any SAE that might be associated with the EDB. 
***Environmental or occupational exposure: AEs or SAEs associated with occupational exposure 
are reported to [COMPANY_007] Safety using the Vaccine SAE Report Form orvia PSSA . 
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 90When an AE or SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic reports) 
related to the event.
The investigator will then record all relevant AE or SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to [COMPANY_007] Safety  in lieu of completion of the Vaccine SAE Report Form /AEor 
SAE CRF page.
There may  be instances when copi[INVESTIGATOR_404205] y .In this case, all participan t identifiers, with the exception of the 
participant number, will be redacted on the copi[INVESTIGATOR_404204] .Refer to Section 10.1.[ADDRESS_799395] be taken 
when medical records are sent to the sponsor or sponsor designee.
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis 
(not the individual signs/sy mptoms) will be documented as the AE or SAE.
Assessment of Intensity
GRADE If required on the AE page of the CRF, the investigator will use the 
adjectives MILD, MODERATE, SEVERE, or LIFE- THREATENING to 
describe the maximum intensity  of the AE. For purposes of consistency , 
these intensity  grades are defined as follows:
1 MILD Does not interfere with participant ’s usual 
function.
2 MODERATE Interferes to some extent with participant ’s usual 
function.
3 SEVERE Interferes significantl y with participant ’s usual 
function.
4 LIFE -THREATENING Life-threatening consequences; urgent 
intervention indicated.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 91Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention and 
each occurrence of each AEor SAE. The investigator will use clinical judgment to 
determine the relationship.
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be 
ruled out.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other risk 
factors, as well as the temporal relationship of the event to study  intervention 
administration, will be considered and investigated.
The investigator will also consult the IB and/or product information, for marketed 
products, in their assessment.
For each AE or SAE, the investigator must document in the medical notes that they 
have reviewed the AE or SAE and have provided an assessment of causality.
There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor . However, it is very 
important that the investigator always make an assessment of causality for every 
event before t he initial transmission of the SAE data to the sponsor .
The investigator may  change their opi[INVESTIGATOR_19954] -up 
information and send a nSAE follow -up report with the updated causality  assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caused the 
event, then the event will be handled as “related to study  intervention ” for reporting 
purposes, as defined by [CONTACT_456] . In addition, if the investigator determines that an 
SAE is associated with study  procedures, the investigator must record this causal 
relationship in the source documents and CRF, and report such an assessment in the 
dedicated section of t
he Vaccine SAE Report Form/PSSA and in accordance with the 
SAE reporting requirements.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 92Follow -Up of A Esand SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations, as medically  indicated or as requested by  [CONTACT_103] ,to elucidate the nature and/or causalit y of the AE or SAE as full y as possible.
This may  include additional laboratory  tests or investigations, histopathological 
examinations, or consultation with oth er healthcare providers .
If a participant dies during participation in the study or during a recognized follow -up 
period, the investigator will provide [COMPANY_007] Safety  with a cop y of an y postmortem 
findings ,including histopathology . 
New or updated information will be recorded in the originally  submitted documents .
The investigator will submit any  updated SAE data to the sponsor within [ADDRESS_799396]
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety will be the electronic 
DCT (eg, eSAE or PSSA) .
If the electronic s ystem is unavailable, then the site will use the paper SAE report form 
(see next section) to report the ev ent within 24 hours.
The site will enter the SAE data into the electronic DCT (eg, eSAE or PSSA) or paper 
form (as applicable) as soon as the data become available.
After the stud y is completed at a given site, the electronic DCT will be taken off -line to 
prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic DCT has been taken off- line, 
then the site can report th is information on a paper SAE form (see next section) or to 
[COMPANY_007] Safety  by [CONTACT_756].
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 93SAE Reporting to [COMPANY_007] Safety via the Vaccine SAE Report Form
Facsimile transmission of the Vaccine SAE Report Form is one of the preferred 
method s to transmit this information to [COMPANY_007] Safety .
In circumstances when the fac simile is not working , an alternative method should be 
used, eg, secured (Transport Lay er Securit y) or password -protected email. If none of 
these methods can be used, 
notification by [CONTACT_9337] a copy  of the 
Vaccine SAE Report Form sent by  [CONTACT_22855].
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the Vaccine SAE Report Form pages withi n the designated reporting 
time frames.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 9410.4. Appendix 4: Contraceptive and Barrier Guidance 
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the intervention period and for at least [ADDRESS_799397] dose of stud y intervention, which 
corresponds to the time needed to eliminate reproductive safe ty risk of the study  
intervention(s) :
Refrain from donating sperm.
PLUSeither :
Be abstinent from heterosexual intercourse as their preferred and usual lifesty le (abstinent 
on a long -term and persistent basis) and agree to remain abstinent .
OR
Must agree to use contraception/barrier as detailed below:
Agree to use a male condom , and should also be advised of the benefit for a female 
partner to use a highl y effective method of contraception as a condom may break or 
leak,when having sexual intercourse with a WOCBP who is not currentl y pregnant.
OR
Be vasectomized, with the absence of sperm having been confirmed.
10.4.2. Female Participant Reproductive Inclusion Criteria
The criteria below are part of inclusion 
criterion 1 (Age and Sex; Section 5.1) and specify  the 
reproductive requirements for including female participants. Refer to Section 10.4.[ADDRESS_799398] 
1of the following conditions applies:
Is not a WOCBP (see definitions below in Section 10.4.3).
OR
Is a WOCBP and agrees to use an acceptable contraceptive method during the 
intervention period (for a minimum of [ADDRESS_799399] dose of stud y intervention). 
The investigator should evaluate the effectiveness of the contraceptive method in 
relationship to the first dose of study  intervention.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 95The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inc lusion of a woman with an earl y undetected 
pregnancy .
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea or olig omenorrhea ) and a menstrual cy cle cannot be 
confirmed before the first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenopausal female with 1 of the following:
Documented h ysterectomy ;
Documented bilateral salpi[INVESTIGATOR_1656] ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to a medical cause other than the above
(eg, mullerian agenesis, androgen insensitivity ), investigator discretio n should be applied to 
determining stud y entr y.
Note: Documentation for any of the above categories can come from the site personnel ’s 
review of the participant ’s medical records, medical examination, or medical history  
interview . The method of documentation should be recorded in the participant ’s medical 
record for the study.
2.Postmenopausal female :
A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. In addition:
A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years of age and not using hormonal 
contraception or HRT. 
A female on HRT and whose menopausal status is in doubt will be required to use 
one of the highly  effective nonestrogen hormonal contra ception methods if she
wishes to continue herHRT during the study . Otherwise, she must discontinue 
HRT to allow confirmation of postmenopausal status before study  enrollment.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 9610.4.4. Contracepti onMethods
Contraceptive use b y men or women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
The following contraceptive methods are appropriate for this study :
Highl y Effective Methods That H ave Low User Dependency  
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device.
3.Intrauterine hormone -releasing s ystem.
4.Bilateral tubal occlusion.
5.Vasectomized partner:
Vasectomized partner is a highl y effective contraceptiv e method provided that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has been 
confirmed. If not, an additional highly  effective method of contraception should be 
used. The spermatogenesis cy cle is approximately  90 day s.
Highl y Effective Methods That A re User Dependent 
6.Combined (estrogen- and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation:
Oral;
Intravaginal;
Transdermal .
7.Progestogen -only hormone contraception associated with inhibition of ovulation:
Oral;
Injectable.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 978.Sexual abstinence
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention. The reliability of sexual abstinence needs to be evaluated 
in relation to the duration of the study and the preferred and usual lifest yle of the 
participant.
Other Effective Methods
9.Progestogen -only oral hormonal contraception where inhibition of ovulation is not the 
primary  mode of action.
10. Male or female condom, with or without spermicide.
11.Cervical cap, diaphragm, or sponge with spermicide.
12. A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods).
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 9810.5. Appendix 5: Liver Safety: Suggested Actions and Follow -Up Assessments 
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “ tolerators, ” while those who show t ransient liver injury but adapt 
are termed “adaptors.” In some participant s, transaminase elevations are a harbinger of a 
more serious potential outcome. These participant s fail to adapt and therefore are 
“susceptible” to progressive and serious liver injury , commonly  referred to as DILI. 
Participant s who experience a transaminase elevation above 3 × ULN should be monitored 
more frequently  to determine if they  are “adaptor s” or are “ susceptible. ”
LFTs are not required as a routine safety  monitoring procedur e in this study . However , should 
an investigator deem it necessary  to assess LFT s because a participant presents with clinical 
signs/sy mptoms, such LFT  results should be managed and followed as described below .
In the majority  of DILI cases, elevations in AST and/or ALT precede T bili elevations 
(>2 × ULN) b y several days or weeks. The increase in T bili ty pi[INVESTIGATOR_1306] y occurs while AST/AL T 
is/are still elevated above 3 × ULN (ie, AST/AL T and T bili values will be elevated within 
the same lab oratory sample). In 
rare instances, by [CONTACT_29623] T bili elevations are detected, 
AST/AL T values might have decreased. 
This occurrence is still regarded as a potential DILI. 
Therefore, abnormal elevations in either AST OR ALT in addition to T bili that meet the 
criteria outline d below are considered potential DILI (assessed per Hy ’s law criteria) cases
and should alway s be considered important medical events, even before all other possible 
causes of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant ’s individual baseline values and underly ing conditions. 
Participant s who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participant s with AST/ALT and T bili baseline values within the normal range who 
subsequently  present with AST OR AL T values ≥3 × ULN AND a T bili value ≥ 2 × ULN 
with no evidence of hemoly sis and an alkaline phosphatase value 2 ×ULN or not 
available.
For participant s with baseline AST OR ALT ORT bili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the U LN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT values 
≥
2times the baseline values AND ≥3 × ULN; or ≥ 8 ×ULN (whichever is smaller).
Preexisting values of T bili above the normal range: T bili level increased from
baseline value b y an amount of ≥ 1 × ULN orif the value reaches ≥3 × ULN 
(whichever is smaller).
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 99Rises in AST/AL T and T bili separated by [CONTACT_726] a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy ’
s law case should be reviewed with the sponsor.
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within [ADDRESS_799400] and ALT and T bilifor suspected Hy ’s law
cases , additional laboratory  tests should include albumin, CK, direct and indirect bilirubin, 
GGT , PT/I NR, 
eosinophils (%) , and alkaline phosphatase. Consideration should also be 
given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for 
furth er testing, as needed, for further contemporaneous anal yses at the time of the recognized 
initial abnormalities to determine etiology . A detailed history , including relevant information, 
such as review of ethanol, acetaminophen /paracetamol (either b y itsel f or as a coformulated 
product in prescription or over -the-counter medications), recreational drug, or supplement 
(herbal) use and consumption, family  history , sexual history , travel history , history  of contact 
[CONTACT_4490] a jaundiced person, sur gery, blood trans
fusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for acute 
hepatitis A, B, C, D, and E infection ,total bile acids, liver imaging (eg, biliary  tract) ,and 
collection of ser um sample sfor acetaminophen /paracetamol drug and/or protein adduct 
levels may  be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
T bili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT  abnormalities has y et been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’
s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page [ZIP_CODE].6. Appendix 6: Kidney Safety Monitoring Guidelines
10.6.1. Laboratory Assessmen t of Change in Kidney Function and Detection of Kidney 
Injury
Standard kidney  safety  monitoring requires assessment of baseline and postbaseline Screat 
measurement to estimate kidney
 function [Screat -based eGFR] or creatinine clearance 
[eCrCl]). Baseline and postbaseline Scy s makes it feasible to distinguish AKI from other 
causes of Screat increase. If Screat increase is confirmed after baseline, then reflex 
measurement of Scy s is indicated. 
ADULTS: Currentl y, 2021 CKD -EPI [INVESTIGATOR_336252] (Screat -only based and combined 
Screat plus Scy s-based) are valid for use in adu lts only . At baseline Screat and Scy s values 
are needed to calculate 2021 CKD- EPI [INVESTIGATOR_510458] -only based equation (see the table in 
Section [IP_ADDRESS]) and b y combined Screat plus Scy s -based equation. When postbaseline 
Screat increase ≥ 0.3 mg/dL  is confirmed, then reflex Scy s measurement is needed to enable 
postbaseline comparison of eGFR changes (Screat -only based eGFR and combined Screat 
plus Scy s eGFR). 
Regardl ess of whether kidney  function monitoring tests are required as a routine safet y 
monitoring procedure in the study , if the investigator or sponsor deems it necessary  to further 
assess kidney  safety  and quantify  kidney  function, then these test results shou ld be managed 
and followed per standard of care.
10.6.2. Age-Specific Kidney Function Calculation Recommendations
[IP_ADDRESS]. Adults (18 Years and Above)—2021 CKD- EPI [INVESTIGATOR_227929] (mL/min/1.73m²)
2021 
CKD -EPI 
[INVESTIGATOR_227931]
(mg/dL)Scys
(mg/L)Recommended eGFR Equation
Female if ≤.7 N/A eGFR = 143 × (Scr eat/0.7)-0.241 × (0.9938)Age
Female if 0.7 N/A eGFR = 143 × (Scr eat/0.7)-1.200 × (0.9938)Age
Male if ≤0.9 N/A eGFR = 142 × (Scr eat/0.9)-0.302 × (0.9938)Age
Male if 0.9 N/A eGFR = 142 × (Scr eat/0.9)-1.200 × (0.9938)Age
2021 
CKD -EPI 
[INVESTIGATOR_227932]-Scys 
CombinedScreat
(mg/dL)Scys
(mg/L)Recommended eGFR Equation
Female if ≤0.7 if ≤0.8 eGFR = 130 × (Scr eat/0.7)-0.219 ×(Scys/0.8)-0.323 ×(0.9961)Age
Female if ≤0.7 if 0.8 eGFR = 130 × (Scr eat/0.7)-0.219 ×(Scys/0.8)-0.778 ×(0.9961)Age
Female if 0.7 if ≤0.8 eGFR = 130 × (Scr eat/0.7)-0.544 ×(Scys/0.8)-0.323 ×(0.9961)Age
Female if 0.7 if 0.8 eGFR = 130 × (Scr eat/0.7)-0.544 ×(Scys/0.8)-0.778 ×(0.9961)Age
Male if ≤0.9 if ≤0.8 eGFR = 135 × (Scr eat/0.9)-0.144 ×(Scys/0.8)-0.323 ×(0.9961)Age
Male if ≤0.9 if 0.8 eGFR = 135 × (Scr eat/0.9)-0.144 ×(Scys/0.8)-0.778 ×(0.9961)Age
Male if 0.9 if ≤0.8 eGFR = 135 × (Scr eat/0.9)-0.544 ×(Scys/0.8)-0.323 ×(0.9961)Age
Male if 0.9 if 0.8 eGFR = 135 × (Scr eat/0.9)-0.544 ×(Scys/0.8)-0.778 ×(0.9961)Age
Inker LA et al. N Engl J Med. 2021;385(19):1737 -49.41
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page [ZIP_CODE].6.3. Kidney Function Calculation Tools
The sponsor has provided the following resources to investigational sites when required to 
calculate age -specific kidney  function at the s creening, baseline, and postb aseline visits. Site 
calculations of kidney  function can be performed manually , using the age -appropriate 
formulae (see Section 10.6.2 ) and can use recommended online kidney  function calculators 
to reduce the likelihood of a calculation error. 
The[LOCATION_002] National Kidney  Foundation Online Calculators. 
Adults (18 y ears and above) 
-2021 CKD -EPI [INVESTIGATOR_227933] (eGFR): 
https://www.kidney .org/professionals/KDOQI /gfr_calculator
Adolescents (12 years to 18 years) -Cockcroft -Gault Formula (eCrCl): 
https://www.kidney .org/professionals/kdoqi/gfr_calculatorCoc
Investigational sites are responsible to ensure that the accurate age -specific equation is 
selected and that the correct units are used for serum creatini ne (mg/dL only ), serum 
cystatin C (mg/L onl y), total body weight (kg only), and age (years). Investigators are 
expected to (i) review and confirm correctness of the kidney  function calculation results 
and (ii) evaluate the calculated value within the conte xt of historical information 
available to them in the participant’s medical record. I nvestigators are responsible for the 
clinical oversight of the participant eligibility  process, kidney function calculation, and 
dose selection and adjustments per study  protocol. I nvestigators are encouraged to direct 
questions or uncertainties regarding kidney  function and dosing to the [COMPANY_007] Clinical 
Team and Medical Monitor, if needed.
10.6.4. Adverse Event Grading for Kidney Safety Lab oratory Abnormalities
AEgrading for decline in kidney  function (ie, eGFR or eCrCl) will be according to KDIGO
criteri a for both pediatric and adult participants.
KDIGO criteria 
grade (G)Study 
PopulationG1 G2 G3 G4 G5
Decreased 
Kidney Function 
due to either 
Acute or Chronic 
Kidney Injury Adult 
participants
eGFR 
(mL/min/1.73m²)≥90 ≥60 to 89 30 to 59 15 to 29 15
KDIGO albuminuria (A) 
criteriaA1 A2 A3
Albumin -to-creatinine ratio 
(ACR)30 mg/g
OR     
3 mg/mmol 30 to 300 mg/g
OR 
3 to 30 mg/mmol300 mg/g 
OR 
30 mg/mmol
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page [ZIP_CODE].7. Appendix 7: A Es , ADEs, SAEs, SADEs, [LOCATION_003]DEs, and Device Deficiencies:
Definition sand Procedures for Recording, Evaluating, Follow -Up, and Reporting in 
Medical Device Studies
Definitions of a Medical Device Deficiency
The definitions and procedures detailed in this appendix are in accordance with I SO [ADDRESS_799401] 2017/745 for clinical device research (if applicable) . 
Both the investigator and the sponsor will comply  with all local reporting requirements for 
medical devices.
The detection and documentation procedures described in this protocol apply  to all sponsor 
medical devices provided for use in the stud y (see Section 6.1.[ADDRESS_799402] of sponsor 
medical devices).
10.7.1. Definition of AE and ADE
AE and ADE Definition
An AE is defined in Appendix 3 (Section 10.3.1 ).
An ADE is defined as an AErelated to the use of an investigational medical device. 
This definition includes any  AEsresulting from insufficient or inadequate instructions 
for use, deplo yment, implantation, installation, or operation, or any  malfunction of the 
investigational medical device as well as an y event resulting from use error or from 
intentional misuse of the investigational medical device.
10.7.2. Definition of SAE, SADE ,and [LOCATION_003]DE
SAE Definition
An SAE is defined in Appendix 3 (Section 10.3.2 ).
SADE Definition
An SADE is defined as an ADE that has resulted in any  of the consequences 
characteristic of an SAE .
Any device deficiency  that might have led to an SAE if appropriate action had not been 
taken, intervention had not occurred, or circumstances had been less fortunate.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 103[LOCATION_003]DE Definition
A [LOCATION_003]DE (also identified as UADE in US Regulation 21 CFR 813.3) is anSADE that
by [CONTACT_5942], incidence, severit y, or outcome has not been identified in the current 
version of the risk analy sis management file .
10.7.3. Definition of Device Deficiency
Device Deficiency Definition
A device deficiency  is an inadequacy  of a medical device with respect to its identity , 
quality , durabilit y, reliability , safet y, or performance. Device deficiencies include 
malfunctions, use errors, and inadequate information supplied by  [CONTACT_3455] .
10.7.4. Recording/Reporting and Follow -Up of Medical Device Deficiencies
Device Deficiency Recording
When a device deficiency  occurs, it is the responsibility  of the investigator to review 
all documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant device deficiency  information in the 
participant’s medical records, in accordance with the investigator’s normal clinical 
practice .  
If an AE (either serious or nonserious) associated with the device deficiency o ccurs, 
then the AE must be entered into the AE section of the CRF.
The investigator will 
notif ythe sponsor study  team by [CONTACT_603739], eg, telephone, 
email within 1 business day  of determining that the incident meets the protocol 
definition of a medical device deficiency .
The sponsor study  team willcapture the required information on the Medical Device 
Complaint formalong with any  associated AE (either serious or nonserious) when 
applicable and send to the appropriate product quality  complaint group .
If the investigator determines that the medical device deficiency  may  have injured the 
participant (ie, the medical device deficiency  is associated with an AE or SAE), then 
the investigator will attempt to establish a diagnosis of the event based on signs,
symptoms, and/or other clinical information. Whenever possible, the diagnosis will be 
documented in the participant’s medical record and recorded as the AE or SAE rather 
than the individual signs/sy mptoms. All relevant details related to the role of the d evice 
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 104in regard tothe SAE must be included in the Vaccine SAE Report Form as outlined in 
Sections [IP_ADDRESS] and [IP_ADDRESS]. 
There may  be instances when copi[INVESTIGATOR_603707] y. In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copi[INVESTIGATOR_404204] . Refer to 
Section 10.1.[ADDRESS_799403] be taken 
when medical records are sent to the sponsor or sponsor designee .
For device deficiencies, it is very  important that the investigator describes any  
corrective or remedial actions taken to prevent recurrence of the incident .
A remedial action is an y action other than routine maintenance or servicing of a 
medical device where such action is necessary  to prevent recurrence of a device 
deficiency . This includes any  amendment to the device design to prevent recurrence.
Assessment of Causality Occu rring in Conjuncti on With a Medical Device Deficiency
If an AE or SAE has occurred in conjunction with a medical device deficiency , the 
investigator must assess the relationship between each occurrence of the AE or SAE 
and the medical device deficiency . The investigator will use clinical judgment to 
determine the relationship.
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be 
ruled out.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other risk 
factors, as well as the temporal relationship of the event to study  intervention 
administration will be considered and investigated.
The investigator will also consult the IB and/or product information, for marketed 
products ,in their assessment.
For each device deficiency , the investigator must documen
t in the medical notes that 
they have reviewed the device deficiency  and ha veprovided an assessment of 
causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is very  
important that the investigator alway s make an assessment of causality  for every  event 
before the initial transmission of the SAE data to the sponsor.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 105The investigator may  change their opi[INVESTIGATOR_19954] -up 
information and send a nSAE follow -up report with the updated causality  assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
Follow -Up of Medical Device Deficiency
Follow -up applies to all participants, including those who discontinue study  
intervention.
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations, as medically  indicated or as requested b y the 
sponsor to elucidate the nature and/or causalit y of the device deficiency  as fully  as 
possible. This may  include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other healthcare providers .
New or updated information regarding the nature of the device deficiency  will be 
recorded in the originall y completed Medical Device Complaint f ormby [CONTACT_603740] .
New or updated information regarding an y SAE that was potentially associated with 
the medical device deficiency  will be submitted to [COMPANY_007] Safety  on the Vaccine SAE 
Report Form within 24 hours of receipt of the information, according to the 
requirements provided in Appendix 3 .
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page [ZIP_CODE].8. Appendix 8: Abbreviations
The following is a list of abbreviations that may  be used in the protocol. 
Abbreviation Term
A1 to A3 albuminuria (KDIGO albuminuria severit y standardization)
ACIP Advisory  Committee on Immunization Practices
ACR albumin -to-creatinine ratio
ADE adverse device effect
AE adverse event
AESI adverse event of special interest
AKI acute kidney  injury
ALT alanine aminotransferase
AST aspartate aminotransferase
AxMP auxiliary  medicinal product
BEVS baculovirus expression vector s ystem
-hCG -human chorionic gonadotropin
BMI body  mass index
BNT162b2 [COMPANY_007] -BioNTech COVID -19 vaccine
BSA body  surface area
CBER Center for Biologics Evaluation and Research ([LOCATION_002])
CDC Center sfor Disease Control and Prevention ([LOCATION_002])
CFR Code of Federal Regulations ([LOCATION_002])
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD -EPI [INVESTIGATOR_159840] K idney  Disease Epi[INVESTIGATOR_603708] -[ADDRESS_799404]
ECG electrocardiogram or electrocardiography
eCrCl estimated creatinine clearance
eCRF electronic case report form
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 107Abbreviation Term
EDB exposure during breastfeeding
e-diary electronic diary
EDP exposure during pregnancy
eGFR estimated glomerular filtration rate
eICD electronic informed consent document
EMA European Medicines Agency
eSAE electronic serious adverse event
EU European Union
EUA emergency  use authorization
EudraCT European Union Drug Regulating Authorities Clinical Trials 
(European Clinical Trials Database)
FDA Food and Drug Administration ([LOCATION_002])
FSH follicle -stimulating hormone
G1 to G5 Grade (KDIGO eGFR category  standardization)
GBS Guillain -Barré syndrome
GCP Good Clinical Practice
GGT gamma -glutamy l transferase
GMFR geometric mean fold rise
GMR geometric mean ratio
GMT geometric mean titer
HA hemagglutinin
HAI hemagglutinin inhibition assay
HBV hepatitis B virus
HCV hepatitis C virus
HIV human immunodeficiency virus
HRT hormone replacement therap y
Ht height
IB investigator’s brochure
ICD informed consent document
ICH International Council for Harmonisation of Technical Requirements 
for Pharmaceuticals for Human Use
ID identification
IgG immunoglobulin G
IMP investigational medicinal product
IND investigational new drug
INR international normalized ratio
IP Internet Protocol
IPAL investigational product accountability  log
IPM investigational product manual
IRB institutional review board
IRC internal review committee
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 108Abbreviation Term
IRT interactive r esponse technology
ISO International Organization for Standardization
IV intravenous(l y)
IWR interactive Web -based response
K Proportionality  constant for Schwartz e quations (kidney  function)
KDIGO Kidney  Disease: I mproving Global Outcomes
LFT liver function test
MDR medical device regulation
modRNA nucleoside -modified messenger ribonucleic acid
MQI medically  qualified individual
mRNA messenger ribonucleic acid
NA neuraminidase
N/A not applicable
NAAT nucleic acid amp lification test
NIMP noninvestigational medicinal product
Omi Omicron
PFS prefilled s yringe
PI [INVESTIGATOR_227947]'s Serious Adverse E vent Submission Assistant
PT prothrombin time
QTL quality  tolerance limit
RCDC reverse cumulative distribution curve
RIV recombinant influenza virus (Flublok Quadrivalent)
RNA ribonucleic acid
S1 spi[INVESTIGATOR_144870] S1 subunit
SADE serious adverse device effect
SAE serious adverse event
SAP statistical analysis plan
SARS severe acute respi[INVESTIGATOR_214322] -CoV -[ADDRESS_799405] upper limit of normal
US [LOCATION_002]
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 109Abbreviation Term
[LOCATION_003]DE unanticipated serious adverse device effect
VE vaccine efficacy
WHO World Health Organization
WOCBP woman/women of childbearing potential
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page [ZIP_CODE].REFERENCES
1Janssen C, Mosnier A, Gavazzi G, et al. Coadministration of seasonal influenza and 
COVID -19 vaccines: a systematic review of clinical studies. Hum Vaccin Immunother. 
2022;18(6):2131166.
2Murdoch L ,Quan K ,Baber JA et al. Safet y and immunogenicit y of the BNT162b2 
vaccine coadministered with seasonal i nactivated influenza vaccine in adults. I nfect Dis 
Ther .
2023;12(9):2241- 58.
3Du L , He Y, Zhou Y, et al. The spi[INVESTIGATOR_119901] -CoV --
a target for vaccine and 
therapeutic development. N at Rev Microbiol. 2009;7(3):[ADDRESS_799406] immune memory  after SARS -CoV -2 infection with persisting antibody  responses 
and memory  B and T cells. Cell Rep Med. 2021;2(7):[ZIP_CODE]
4.
5Viper Group COVID19 Vaccine Tracker Team. COVID19 vaccine tracker: 
[COMPANY_007]/BioNTech: Comirnaty .  Available from: 
https://covid19.trackvaccines.org/vaccines/6/. Accessed: 02 Jun 2023.
6FDA. FDA roundup: July  8, 2022. Available from: https://www.fda.gov /news -
events/press -announcements/fda -roundup -july-
8-2022. Accessed: 11 Feb 2023.
7WHO. Statement on the antigen composition of COVID -19 vaccines. Available from: 
https://www.who.int/news/item/18 -05-2023- statement - on -the-antigen -composition -of-
covid-19- vaccines. Published: 18 May  2023. Accessed: 25 May  2023.
8Link -Gelles R, Ciesla AA, Roper LE, et al. Earl y estimates of bivalent mRNA booster 
dose vaccine effectiveness in preventing s ymptomatic SARS -CoV -2 infection 
attributable to Omicron BA.5 -and XBB/XBB.1.5- related sublineages among 
immunocompetent adults -increasing community  access to testing program, United 
States, December 2022 -January  2023. MMWR Morb Mortal Wkly  Rep. 
2023;72(5):119 -24.
9Surie D, DeCuir J, Zhu Y, et al. Earl y estimates of bi valent mRNA vaccine effectiveness 
in preventing COVID -19–associated hospi[INVESTIGATOR_603709] ≥65 y ears —IVY Network, 18 states, September 8–November 30, 2022. MMWR 
Morb Mortal Wkly  Rep. 2022;71(5152):1625 -30.
10Tenforde MW, Weber ZA, Natarajan K, et al. Early  estimates of bivalent mRNA 
vaccine effectiveness in preventing COVID -19–associated emergency  department or 
urgent care encounters and hospi[INVESTIGATOR_603710] —VISION 
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 111Network, nine states, September –Novem ber 2022. MMWR Morb Mortal Wkly  Rep. 
2023;71(53):[ADDRESS_799407] severe COVID- 19 after 
second booster dose of adapted bivalent (original/Omicron BA.4 -5) mRNA vaccine in 
persons ≥  60 y ears, by  [CONTACT_603741], I taly, 12 September to 11 December 2022. 
Euro Surveill. 2023;28(8):2300105. DOI: 10.2807/1560- 7917.ES.2023.28.8.2300105.
12Link -Gelles R. CDC. COVID -19 vaccine effectiveness updates. Data presented at the 
ACIP meeting (19 April 2023). Avai lable from: 
https://www.cdc.gov/vaccines/acip/meetings/downloads/slides -2023-04- 19/05 -COVID -
Link -Gelles
-508.pdf. Accessed: [ADDRESS_799408] severe Omicron 
infection. N Engl J Med. 2023;388 (8):764-6.
14Link -Gelles R, Weber ZA, Reese SE, et al. Estimates of bivalent mRNA vaccine 
durability  in preventing COVID-19–associated hospi[INVESTIGATOR_603711] —VISION Network, 
Septem ber 2022
–April 2023. MMWR Morb Mortal Wkly  Rep. 2023;72(21):579-88.
15Poukka E, Nohy nek H, Goebeler S, et al. Bivalent booster effectiveness against severe 
COVID -19 outcomes in Finland, September 2022 —March 2023. medRxiv 2023. 
DOI: https://doi.org/10.1101/2023.03.02.23286561. Available from: 
https://www.medrxiv.org/content/10.1101/2023.03.02.23286561v3. Accessed: 
30 Jun 2023.
16Carabelli AM, Peacock TP, Thorne LG, et al. SARS -CoV -2 variant biology : immune 
escape, transmission a nd fitness. Nat Rev Microbiol. 2023;21(3) :162-77. DOI : 
https://doi.org/10.1038/s41579 -022-[ZIP_CODE] -7.
17Regan JJ, Moulia DL , Link-Gelles R, et al. Use of updated COVID -19 vaccines 2023 –
2024 f ormula for persons a ged ≥6 months: recommendations of the Advisory  
Committee on I mmunization Practices — [LOCATION_002], September 2023. MMWR 
Morb Mortal Wkly  Rep. 2023;72(42) :1140 -6.
18Cunha BA. Influenza: historical aspects of epi[INVESTIGATOR_603712]. Infect Dis Clin 
North Am. 2004;18(1):141 -55.
19Monto AS, Gravenstein S, Elliott M, et al. Clinical signs and s ymptoms predicting 
influenza infection. Arch I ntern Med. 2000;160(21):3243 -7.
20Cowling BJ, Chan KH, Fang VJ, et al. Comparative epi[INVESTIGATOR_603713] A in households. N Engl J Med. 2010;362( 23):2175-84.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 11221Hall E. Influenza. Chapter 12. In: Epi[INVESTIGATOR_528850] -preventable 
diseases. 14th ed. CDC. Hall E, Wodi AP, Hamborsky  J, et al, eds. Washington, DC: 
Public Health Foundation; 2021:179-92.
22Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza -
associated respi[INVESTIGATOR_603714] : a modelling study. L ancet. 2018;391([ZIP_CODE]):1285 -300.
23Cox NJ, Subbarao K. Influenza. Lancet. 1999;354(9186):1277 -
82.
24Milian E, Kamen AA. Current and emerging cell cultur e manufacturing technologies for 
influenza vaccines. Biomed Res Int. 2015;2015:[ADDRESS_799409] track influenza virus vaccine produced in inset cells. J 
Invert ebrPathol. 2011;[ADDRESS_799410] :S31-S41.
26CDC. Summary : ‘Prevention and control of seasonal influenza with vaccines: 
recommendations of the Advisory  Committee on Immunization Practices (ACI P)—
[LOCATION_002], 2023- 24.’ Available from: 
https://www.cdc.gov/flu/ pdf/professionals/acip/acip -2023-24- Summary -Flu-Vaccine -
Recommendations.pdf . Published: 23 Aug 2023. Accessed: [ADDRESS_799411] 2023.
27Polack FP, Thomas SJ, Kitchin N, et al. Safet y and efficacy of the BNT162b2 mRNA 
Covid -19 vaccine. N Engl J Med. 2020;383(27):2603 -
15.
28[COMPANY_007]. [COMPANY_007] and BioNTech confirm high efficacy  and no serious safet y concerns 
through up to six months following second dose in updated topline anal ysis of landmark 
COVID -19 vaccine study [press release]. Available from: 
https://www.pfizer.com/news/press -release/press- release -detail/pfizer -and-biontech -
confirm -high-efficacy -and-no-serious. Published: 01 Apr 2021. Accessed: 25 Feb 2022.
29ECDC, EMA. ECDC
-EMA statement on updating COVID -19 vaccines composition for 
new SARS -CoV -2 virus variants. Available from:
https://www.ema.europa.eu/en/documents/other/ecdc -ema-statement -updating -covid -19-
vaccines -composition -new-sars-cov-
2-virus -variants_en.pdf. Published: 06 Jun 2023. 
Accessed: 22 Jun 2023.
30FDA. Updated COVID -19 vaccines for use in the [LOCATION_002] beginning in fall 2023 
[press release]. Available from: https://www.fda.g ov/vaccines -blood -biologics/updated -
covid
-19-vaccines- use-united -states -beginning -fall-2023. Published: 16 Jun 2023. 
Accessed: 22 Jun 2023.
31FDA . [COMPANY_007] - BioNTech COVID-19 vaccine , 11 Sep 2023. Available from: 
https://www.fda.gov/vaccines -blood -biologics/coronavirus
-covid-19- cber-regulated-
biologics/pfizer -biontech -covid-19- vaccine . Accessed: 14 Sep 2023.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
PF-08044562 (Combination COVID- 19 Vaccine and RIV)
Protocol C568 1001
Final Protocol, 18 December 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
Page 11332Keitel WA, Treanor JJ, El Sahly  HM, et al. Comparative immunogenicit y of 
recombinant influenza hemagglutin in (rHA) and trivalent inactivated vaccine (TIV) 
among persons > or =65 years old. Vaccine. 2009 Dec 11;28(2):379 -85.
33Flublok Quadivalent P rescribing Information. [COMPANY_011] Pasteur. Available from: 
https://www.fda.gov/media/123144/download?attachment. A ccessed:18 Nov 2023.
34Treanor JJ, El Sahly  H, King J, et al . Protective efficacy  of a trivalent recombinant 
hemagglutinin protein vaccine (FluBlok®) against influenza in healthy  adults: a 
randomized, placebo -controlled trial . Vaccine. 2011;29(44):7733
-9.
35Baxter R, Patriarca PA, Ensor K, et al. Evaluation of the safet y, reactogenicity  and 
immunogenicit y of FluBlok®trivalent recombinant baculovirus -expressed 
hemagglutinin influenza vaccine administered intramuscularl y to health y adults 50-64 
years of age. V accine. 2011;29(12):2272-8.
36Dunkle L M, Izikson R, Patriarca PA, et al . Randomized comparison of immunogenicit y 
and safety of quadrivalent recombinant versus inactivated influenza vaccine in health y 
adults [ADDRESS_799412] Dis. 2017;216(10):12 19-26.
37FDA. Guidance for industry : toxicity  grading scale for healthy  adult and adolescent 
volunteers enrolled in preventive vaccine clinical trials. Rockville, MD: Center for 
Biologics Evaluation and Research; September 2007. Available from: 
https://www .fda.gov/media/[ZIP_CODE]/download. Accessed: 10 Aug 2023 .
38Hall KT, Stone VE, Ojikutu B. Reactogenicity  and concomitant administration of the 
COVID -
19 booster and i nfluenza vaccine. JAMA Netw Open. 2022;5(7):e2222246 .
39Comirnaty Prescribing Information. 
[COMPANY_007] . Available from: 
https://www.fda.gov/media/151707/download?attachment . Accessed: 10 Dec2023.
40Agresti A. Introduction: distributions and inference for categorical data. Chapter 1. In: 
Agresti A, ed. Categorical data anal ysis. 2nd ed. Hoboken, NJ: John Wiley  & Sons; 
2002:1 -35.
41Inker LA, Enean ya ND, Coresh J, et al. New creatinine -and cy statin C -based equations 
to estimate GFR without race. N Engl J Med. 2021;385(19):1737-49.
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
Document Approval Record
Document Name:	

	
	

Document Title:	 !"#$%&$ '(%$$)$&
$ (*"("$&"!!% +""$& )! ")" 
'",	-'" !*"$")(%#'"
!""$"+(".$" "($&%($
&
 )+  (
Signed By: [CONTACT_1782](GMT) Signing Capacity
	,,
	22	 *34
44(
556
	,,
	282 )
556
090177e19f7ceb11\Approved\Approved On: 18-Dec-2023 16:34 (GMT)
[COMPANY_003]
[COMPANY_003]